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ABSTRACT OF DISSERTATION
A Microfluidic Platform to Investigate the Mechanism by which GDNF Overexpression in
Schwann Cells Causes Neuronal Axon Entrapment
By Ze Zhong (Bill) Wang
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2019
Professor Dennis Barbour, Chair
Professor Shelly Sakiyama-Elbert, Co-Chair
Twenty million Americans suffer from peripheral nerve injury (PNI) caused by trauma and
medical disorders, with approximately $150 billion spent in annual health-care dollars in the
United States. Even with proper surgical reconstruction, less than 50% of the patients achieve
satisfactory functional recovery. The gold standard surgical repair for long gaps (>3cm) is the
autologous nerve graft, despite its disadvantages such as donor site morbidity, risk of infection,
and increased cost. Alternative methods, such as acellular nerve grafts (ANA), are ineffective for
large lesion gaps because of the lack of cells and regeneration factors. Recent efforts have been
focused on the application of exogenous growth factors, based on their roles during development
and post-injury. Of particular interest for this study, following PNI, the distal nerve and denervated
muscles increase expression of glial cell line-derived neurotrophic factor (GDNF) to stimulate
axonal growth. However, the duration of this response is often insufficient to promote the full
reinnervation of end-organ targets, especially for large injury gaps. To extend the period of release
of GDNF, our lab has previously engineered transgenic SCs with constitutive overexpression of
GDNF (G-SCs). However, we and others have also discovered that such constitutive GDNF

xi

overexpression causes axon entrapment in vivo. Specifically, regenerating axons fail to extend
beyond the GDNF source and form dense nerve coils at the site of overexpression, a phenomenon
termed the “candy-store” effect. The mechanism by which GDNF overexpression causes the
“candy-store” effect is unclear. Moreover, the complexity of the in vivo environment presents a
major challenge to effectively study the “candy-store” effect. Therefore, in this dissertation, we
developed a microfluidic platform to model axon entrapment in vitro and studied the mechanism
by which high levels of GDNF can cause the “candy-store” effect.
First, we recapitulated neuronal axon entrapment using dissociated chicken embryonic
dorsal root ganglion (DRGs) in a 3-chamber microfluidic device. Consistent with in vivo results,
G-SCs were able to cause axon entrapment in this platform. Importantly, we found that a high
concentration of soluble GDNF (700ng/mL) is sufficient to induce axon entrapment. In addition,
axon entrapment caused by high GDNF concentration cannot be overcome by distal sources of
high GDNF levels. To further investigate the underlying mechanism, we used DNA microarray to
identify differentially expressed genes in neurons treated with high GDNF. Slitrk4 was upregulated
by high GDNF treatment, and the knockdowns of Slitrk4 resulted in reduced axon entrapment.
Similar to the effects of soluble GDNF, G-SCs resulted in non-reversible axon entrapment that
cannot be overcome by distal sources of high GDNF levels. We also examined the effects of SCs
preconditioned with high GDNF on neurite extension. While high GDNF preconditioned SCs also
induced axon entrapment, such effect was reversible when distal sources of high GDNF levels
were present. Together, our results have highlighted the mechanism by which GDNF can cause
neuronal axon entrapment and may contribute to developing drug delivery strategies that harness
only the beneficial effects of GDNF while avoiding the negative impact.

xii

Chapter 1: Introduction
1.1 Overview
This work seeks to understand the effects of glial cell-line derived neurotrophic factor
(GDNF) in high concentrations on axon growth and Schwann cell (SC) in vitro. SCs are glia in the
peripheral nervous system (PNS) that are involved in axon guidance, growth, and myelination.
More importantly, they are critical for axon regeneration following peripheral nerve injury (PNI).
Patients suffering from proximal injuries are less likely to recover, as regenerating axons need to
travel long distances (that takes an extended time) to reconnect to the end-organ targets 1. This
chronic denervation can cause neuronal apoptosis and SC atrophy, both of which severely impede
axon regeneration 2. Following PNI, the SCs in the distal nerve and denervated muscles increase
the expression of GDNF to stimulate axonal growth 3. However, the duration of this response is
often insufficient to promote the full reinnervation of end-organ targets, especially for large gap
injury 4. To extend the period of GDNF expression, our lab has previously engineered transgenic
SCs to constitutively overexpress GDNF (G-SCs) 5,6. However, we and others have also found that
constitutive GDNF overexpression causes axon entrapment in vivo 7,8. Specifically, regenerating
axons fail to extend beyond the GDNF source and form dense nerve coils at the site of
overexpression, a phenomenon termed the “candy-store” effect

8,9

. The mechanism by which

GDNF overexpression causes the “candy-store” effect is unclear. Moreover, the complexity of the
in vivo environment presents a major challenge to effectively study the “candy-store” effect. The
current thesis aimed to understand the underlying mechanisms of how GDNF can affect axonal
regeneration and impact the growth-promoting ability of SCs to induce axon entrapment. This
work aimed to recapitulate the “candy-store” effect in vitro by first developing an in vitro culture
1

platform using a 3-chamber microfluidic device. The underlying mechanism by which GDNF
causes the axon entrapment was also investigated.
The first part of this work focused on modeling the “candy-store” effect in vitro. Studying
the “candy-store” effect in vivo can be difficult, given the complexity of the environment and
involvement of multiple cell types in the PNS. Standard in vitro culture systems also lack the
means to separate neuronal soma from axons for effectively studying the causes of axon
entrapment. An in vitro model system was created to recapitulate axon entrapment using a 3chamber microfluidic device. The device consists of three culture chambers (somal, middle, and
distal) connected by microchannels that prevent cell somas from moving between chambers while
allowing neurites to grow between chambers. Since the G-SCs overexpress GDNF, neurons were
cultured under high GDNF concentrations to model axon entrapment. Soft lithography was used
to fabricate the microfluidic device. Axon entrapment was evaluated based on the number of axons
that fail to extend beyond the middle chamber.
The second focus of this thesis is centered on understanding the mechanism by which high
GDNF levels directly affect neurons and also impact the growth-promoting ability of SCs to induce
axon entrapment. Previous work suggests that axon entrapment is mediated either directly by high
GDNF concentrations and/or SCs that are affected by high GDNF concentration. Exposing SCs to
a physiological level of GDNF (preconditioned SCs, 100 ng/mL) promotes axon growth. In
contrast, G-SCs, which express a supra-physiological level of GDNF, induce axon entrapment. In
addition, DNA microarray data indicates that G-SCs have a distinct gene expression profile
compared to normal SCs and SCs preconditioned with GDNF. By using the microfluidic device
designed in the previous study, SCs pretreated with physiological and supra-physiological
concentrations of GDNF or G-SCs were cultured in the middle chamber. Axon growth was

2

assessed under these conditions to evaluate the impact on axons crossing the middle chamber
toward the distal chamber. To understand the effects of different levels of GDNF on neurons, we
used DNA microarrays to reveal potential gene targets related to axon entrapment. In addition,
RNA interference was used on the target genes to investigate their role in entrapment induced by
GDNF.
The following introduction will highlight the characteristics and biology of PNI, the role of
SCs in promoting peripheral nerve regeneration, and the importance of growth factors in enhancing
this process. More importantly, the use of GDNF on peripheral nerve regeneration and its
limitations will be discussed. Current treatment strategies will also be discussed.

1.2 Peripheral Nerve Injury
PNS is one of two branches of the nervous systems. Whereas the central nervous system
(CNS) includes the brain and the spinal cord, the PNS extends outside the CNS and serves to
control the movement of the limb as well as providing sensory feedback to the CNS. PNI caused
by trauma and medical disorders affects twenty million Americans, incurring a cost of
approximately $150 billion in healthcare 10,11. It was estimated that PNI constitutes as 2-3% of all
patients admitted to a Level I trauma center, and can be as high as 5% when plexus and nerve root
injuries are included 12,13. Damage to the PNS can result in impaired motor and/or sensory nerve
function and denervated end-organs. While the PNS has greater inherent capabilities for
regeneration compared with the CNS, the regeneration process faces many challenges that can
greatly limit functional recovery of patients and severe nerve injury often has a devastating impact
on a patient’s quality of life. This section will describe PNI and regeneration as well as the
challenges for functional recovery.

3

1.1.1 Neurobiology of Peripheral Nerve Injury and Regeneration
Many factors, including the patient’s age, the delay before surgical intervention, and the
type of injury, affect the recovery of PNI. The most common causes of PNIs are laceration, crush,
and nerve stretch injuries 14,15. In the upper limb extremity, radial, ulnar, and median nerve injuries
are the most common 12. Sciatic, peroneal and tibial/femoral are the most common in the lower
limb 16. In general, patients suffering from complete transection of nerves are less likely to recover
than from crush injuries. More importantly, the proximity of the injury to the nerve cell body can
greatly impact the degree of recovery. Distal injuries, such as sensory loss to a fingertip, can often
regenerate well. In comparison, proximal brachial plexus avulsions, where the injury site is close
to the cell body, often result in poor recovery with limited hand sensation and reduced motor
function.
Following injury, molecular and cellular changes occur at different levels of the PNS. At
the neuron soma, the withdrawal of trophic support from target organs can significantly influence
neuronal survival. Critical transcriptional changes occur, which will determine whether to induce
apoptosis or promote regeneration in neurons 17. The incidence of apoptosis-related cell death in
dorsal root ganglion neurons following axonotmesis ranges from 20 to 50% 18,19. Distal segments
of the nerve to the injury site also experience profound molecular and cellular changes, a
phenomenon known as Wallerian degeneration (WD). This process allows for the distal nerve
segment to be prepared for regenerating axons by clearing distal axon segments and myelin debris
20,21

22

. Within a few hours after injury, both the axon and the myelin in the distal stump degenerate

. One of the key components that distinguish the PNS from the CNS is the ability of Schwann

cells (SC) to assist this degeneration process. Myelin debris is inhibitory to regenerating axons (as
in the CNS). In the first 24hr, the denervated SCs de-differentiate into an immature state that

4

proliferate and migrate towards the site of axon and myelin breakdown. With the combined actions
of SCs and macrophages, inhibitory debris is removed 23. SCs then align in the remaining basal
lamina and endoneurial tubes to form the bands of Bungner. These structures are formed when the
SCs lay down extracellular matrix (ECM) and organize into columnar tracks for regenerating
axons to follow24,25. At the same time, SCs begin to upregulate surface proteins, such as neural cell
adhesion molecules (NCAM), and secrete neurotrophic proteins, such as nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), and glial cell-line derived neurotrophic factor
(GDNF) 26,27. Additional trophic support is also provided by the end target organs, such as muscles
and skin 28. After migrating through the endoneurial tubes, the axons are myelinated by SCs and
reestablish connections with target end-organs. Correct reinnervation of the end-organ signals that
the axons are fully matured.

1.1.2 Challenges in Peripheral Nerve Regeneration
Several major challenges can hinder functional recovery in the PNS. One of the critical
barriers caused by proximal injuries is chronic denervation. Since axons may take months to years
to cross long injury gaps (>2cm), chronic denervation causes SCs and target tissue to atrophy. SCs
stop maintaining bands of Bungner, and the basal lamina also degenerate and disappear

29

. In

addition to these changes, SCs lose their ability to provide trophic support and become inefficient
at promoting axon growth

30,31

. Similarly, target organs also experience atrophy due to chronic

denervation. Noticeable decreases in the number and size of muscle fibers, along with increases in
fibrosis are observed 32. Even when reinnervation of the muscle eventually occurs, full functional
recovery of muscles is rarely observed. In animal models of chronic denervation, regenerated
axons were observed to be near target muscles. However, these axons have minimal branching and
failed to form synapses, suggesting that the muscles are no longer receptive to innervation by axons

5

33

. Another obstacle caused by proximal injury is chronic axotomy where the axons lost contact

with the target tissue for an extended time. Both sensory and motor neuron showed significant
decreases in number after chronic denervation 19,34.
Even when axons can eventually reach target organs, the regenerating axons may incorrectly
reinnervate the wrong end-organ target. The disruption of endoneurial tubes can lead to
inappropriate reinnervation, where motor axons may reinnervate sensory organs and vice versa
35,36

. If a functionally unrelated end organ is reached, further development of the axon and

remyelination do not occur. Another issue with reinnervation occurs when cross-reinnervation
occurs even when a sufficient number of motor axons reach the muscles. Erroneous crossreinnervation may result in an originally “fast” muscle reinnervated by axons previously
innervating “slow” muscle, and the result may be a mixed form with inefficient contraction

22

.

Overall, there remain many challenges facing axonal regeneration and functional recovery.
Chronic denervation and chronic axotomy reduce the growth potential of neurons, SCs, and target
organs. Even with sufficient axon growth, functional recovery could be impaired by incorrect
reinnervation. Therefore, to design adequate therapies to promote correct axonal regeneration, all
of these factors need to be considered.

1.2 PNI Treatment Strategies
1.2.1 Nerve Repair Using Biological Grafts
Different repair strategies are used based on the severity and type of PNI. For injuries that
require surgical intervention, direct nerve repair with epineural microsutures is performed when a
tension-free coaptation in a well-vascularized bed can be achieved 2. This technique lines up both
the internal nerve fascicles and the surface epineural blood vessel patterns, thus achieving gross
fascicular matching between the proximal and distal nerve ends. Another technique involves
6

grouped fascicular repair and direct matching and suturing of the fascicles. However, more trauma
and scarring offset the advantages of better fascicle alignment with this approach. Functional
outcomes using group fascicular repair is not better than epineural repair 18. The difficulties with
direct nerve repair include reproducing the original alignment of nerve fascicles and minimizing
tension. One requirement for direct repair is removing entire damaged nerve segment to prevent
scar formation, which inhibits regeneration, and revealing the normal fascicular pattern for
regenerating axons to maintain alignment across the coaptation

37,38

. For injuries that require

extensive tissue remove, end-to-end coaptation could cause longitudinal tension, which can result
in chronic ischemia and damage to the endoneurial structure 39,40.
When a tension-free primary repair is not possible, nerve grafts can be used to bridge injury
gaps. Commonly used grafts include autologous nerve graft (autograft) and acellular nerve
allograft (ANA). Autograft is considered the gold standard for bridging long injury gaps (>3cm),
more proximal injuries, and critical nerves

41

. Similar to joining distal nerve segment in direct

repair, autografts provide a permissive and stimulating scaffold, including Schwann cells, basal
laminae, neurotrophic factors, and adhesion molecules 39. Since donor nerves are harvested from
patients, the autografts are also nonimmunogenic compared to cadaveric nerve allografts. The
choice of autograft depends on the size of the nerve gap, location of the proposed nerve repair, and
associated donor-site morbidity 37. The sural nerve from the leg is the most commonly used donor
nerve. Other nerves that are also harvested include the medial antebrachial cutaneous nerve, the
lateral antebrachial cutaneous nerve, dorsal cutaneous branch of the ulnar nerve, superficial and
deep peroneal nerves, intercostal nerves, and the posterior and lateral cutaneous nerves of the thigh
42,43

. Even though autograft is the clinical standard of repair for long injury gaps, it presents several

major drawbacks. First, the size of the autograft is limited. Studies showed that trunk grafts from

7

a large nerve could result in central necrosis and fibrosis due to inadequate vascularization

44,45

.

Also, the donor graft and the repaired nerve need to match in the diameter and number of fibers.
Small sensory nerves are less effective than phenotype matched motor grafts in promoting
regeneration in large diameter motor nerves

46,47

. Another cause for inefficient regeneration also

stems from matching sensory grafts with motor branches. Because sensory loss is preferred over
the motor deficit, sensory nerves are usually sacrificed. However, motor regenerating axons show
preferential motor reinnervation, a process in which motor axons will preferentially reinnervate
muscle over skin 48. This process makes sensory grafts less desirable for repairing motor function.
Other complications of autografts include donor site morbidity leading to sensory loss, neuroma
formation, and the need for a second incision to harvest donor nerve.
As an alternative strategy, cadaveric nerve allografts present several advantages over
autografts. Compared to autografts, cadaver supply is more plentiful than autografts. In addition,
there is no donor site morbidity. It also eliminates the need for second surgeries to harvest donor
nerves, which may result in complications. In clinical practice, allografts have been used to
successfully repair nerve gaps up to 70 mm 49. Although nerve allografts are a potential alternative
to autografts, immunogenicity must be considered. SCs and myelin within allografts can elicit host
rejection, thereby necessitating concurrent immunosuppression for up to two years 2. Until host
SCs can completely replace and populate the donor nerve, donor SCs have to act as support cells
for remyelination. However, donor SCs are also the major contributor to immunogenicity as they
are the primary sources of major histocompatibility complex II molecules 50. This drawback led to
strategies to reduce immunogenicity.
Several techniques have been developed to reduce allograft immunogenicity leading to the
development of acellular nerve allograft (ANA). In particular, decellularization of allogeneic nerve

8

reduces immunogenicity by eliminating antigenic factors, such as Schwann cells and myelin, while
retaining the natural basement membrane and three-dimensional ECM to guide axonal
regeneration

51,52

. Common strategies include cryopreservation and detergent decellularization.

Cryopreservation involves cold preservation of the graft in the University of Wisconsin Cold
Storage Solution at 5°C for seven days, which will preserve the basal lamina and laminin
distribution 53. Viability of the SCs also decreased with increasing time of cold storage. As a result,
immune response and graft rejection were decreased, and regeneration was increased. Combined
with FK-506, which has been demonstrated to augment axon regeneration, cryopreservation has
produced reliable and robust clinical outcomes

54–56

. An alternative strategy for decellularization

is to use detergent. Using amphoteric detergents sulfobetaine (SB)-10 and SB-16, and an anionic
detergent, Triton X-200, Hudson et al. found that optimized antigen removal protocol that causes
minimal damage to the ECM and basement membrane 57. In a 14-mm rat sciatic nerve injury model,
Moore et al. showed that detergent-processed allograft promoted axon regeneration and muscle
force similar to isograft and superior to both the commercially available ANA, AxoGen and
cryopreserved allograft 58. Even though ANA offers as an alternative to autografts for short injury
gaps (<3cm), they are not effective for gaps greater than 4 cm 59. Therefore, alternative strategies
for repairing long gap injuries must be developed.

1.2.2 Nerve Guidance Conduits
Recent research has been focusing on developing nerve guidance conduits (NGC). The
most studied material for NGCs is collagen. Commercially available NGCs are composed of
collagen type I, III, or IV. It can be used as both a conduit material as well as a luminal filler. It is
important to recognize the effects of collagen on different cell types to better design NGCs. In the
PNS, collagen trimers are essential for basal lamina ECM assembly, which is critical for SCs

9

maturation and myelination

60–62

. In vitro studies showed that various types of collagen seem to

have different effects on cells. For instance, α4 Type V collagen promoted SC adhesion and
migration but inhibited dorsal root ganglion neurite outgrowth 63,64. Upon further examination, it
was shown that the collagen domain of Type V blocked neurite outgrowth, while the non-collagen
N-terminal domain improved neurite outgrowth as well as promoting SC migration. These findings
highlight the importance of using different collagen types and derivatives for different purposes
and cell types. Using a combination of the right collagen and matching cells might significantly
impact the regenerative potential of the collagen scaffold. Currently, bovine collagen Type I is the
primary collagen type used in FDA-approved nerve conduits, such as NeuraGen®, NeuroFlex™,
and NeuraWrap™. In particular, NeuraGen has been extensively studied and used in clinical
settings 65,66. Mackinnon et al. conducted the first trials using collagen-based material showing no
occurrence of compression neuropathy in comparison with other more rigid or silicon materials in
a

65

. A later study compared the effectiveness of collagen-based conduit to autograft and direct

suturing in repairing 4mm gap in rat and non-human primate nerves 66. The results show that by
12 weeks, the collagen-based conduits showed similar recovery to autografts and direct suturing.
Later clinical studies also demonstrated the use of NeuraGen in patients with injury gaps ≤ 2cm 67.
Analysis of 126 repairs in 96 patients that received NeuraGen showed minimal complications and
sensory recovery in the 35%-45% range. Compared with autografts, collagen-based conduits are
abundant. They also represent little immunogenicity. However, one major drawback of collagenbased conduits is batch-to-batch variations can compromise reproducible performance.
Synthetic NGCs are gaining more attention in recent years. Synthetic polymers, such as
poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and poly(lactic-co-glycolic acid) (PLGA), are
usually synthesized to form porous scaffold fabrication due to the superior control over porosity

10

and pore diameters 68–71. Synthetic polymers are also tunable and offer a great range of mechanical
and physical properties, such as tensile strength, elastic modulus, and degradation rate. With
defined purity and properties, these characteristics are highly reproducible. The major
disadvantages of synthetic polymers, however, might be limited biocompatibility, lack of natural
cell adhesion sites, cytotoxicity of solvents for fabrication, and release of toxic degradation
products. Early studies on neural scaffold fabrication used non-degradable materials. Silicone was
one of the most prevalent materials used. However, the silicone tube is known to cause discomfort
in patients due to its rigidness

72

. Second surgeries are required to remove the silicone tubes.

Currently, silicone is primarily used as an experimental model for studying PNI. Even though
many positive results have been reported using non-degradable NGC, the challenges remain as
non-degradable scaffold require a second surgery to remove or must be planned for permanent
implantation. For PNI, non-degradable material can cause swelling and nerve compression in longterm implantation. Therefore, non-degradable materials are not the focus of current research
endeavors.
PLA and PGA are two of the most extensively studied biodegradable polyester links of
lactic and glycolic acid. It has been shown SCs embedded in PGA-based tissue-engineered nerve
combined with pluronic F127 gel resulted in comparable numbers of regenerated axons to
autograft control in 10 mm gap sciatic nerve injury in rats 68. PGA conduits with SCs improved
hind limb movements comparable to the autograft while silicone conduits showed a much lower
score. It is important to note that the degradation products of PLA and PGA usually result in a
lower pH of the surrounding environment, which is toxic to the cells. Another well-studied
polyester is PLGA, which is a copolymer of PLA and PGA. SC transplantation in PLGA foam
guides combined with glial growth factor (GGF) showed improvement on axonal regeneration and
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conduction velocity in 10 mm-gap sciatic nerve injury model in rats 70. In addition, PLGA conduit
embedded with olfactory ensheathing cells (OEC) demonstrated an increase in conduction velocity
of nerve fibers 16 weeks after injury, when used to repair a 15 mm-gap sciatic nerve injury in rats
73

. Transplanted OECs showed positive expression of S100β and signs of ECM deposition.

1.3

Schwann Cells
Schwann cells (SC) are the glial population of the PNS. The primary functions of SCs are

myelination for large diameter axons and trophic support for small diameter axons in uninjured
nerves. After injuries, SCs are responsible for removing debris from myelin and axon in distal
segments of the injured nerve. They also release cytokines that will recruit macrophages to help
with debris clearance. In addition, SCs release many neurotrophic factors and express cell adhesion
molecules that promote axon growth. Bands of Bungner formed by SCs after injury provide
structural support for regenerating axons to grow. Both providing critical functions for uninjured
nerve and supporting axon regeneration after injury make studying SCs an essential task for
developing therapeutics for PNI.

1.3.1 Overview of Schwann Cells
SCs originate from neural crest cells (NCCs). While the exact signaling cascade that direct
NCCs towards SC lineage is unclear, Sox10 is thought to be one of the central transcription factors
for generating the earliest cells in the SC lineage

74,75

. Schwann cell precursors (SCPs) are

generated from migrating NCCs. Sox10 null mutant knockouts have shown development arrests
prior to the generation of SC precursors (SCPs). SCPs have the potential to become immature SCs
or endoneurial fibroblasts 76. One of the most important events happening during this stage is SCaxon interaction. Unlike SCs which can survive based on autocrine signaling, SCPs depend
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entirely on juxtacrine signals from axons. Neuregulin-1 (NRG1) and ErbB interactions are a
critical survival factor SCP

23,77

. Absence of NRG1 not only reduced SCP survival but also

negatively impact neuron survival 75,78,79. Another important function of NRG and ErbB signaling
pathway may be related to myelin formation. Knockdown of ErbB 2 results in hypomyelination of
peripheral nerve 80,81. Lack of NRG1 type III in dorsal root ganglion neurons results in defective
axonal ensheathment and lack of myelination 82.
Notch signaling, being another important signaling mechanism in SC, has shown multiple
roles. During development, Notch is likely acting as a maturation signal for SCPs, a mitogen for
immature SCs, and an inhibitor of myelination 83. In mice, genetic inactivation of Notch1 or the
transcription factor RBPJ, which is essential for classical Notch signaling, delayed the generation
of Schwann cell from precursors. Conversely, Schwann cells appear more rapidly in mice in which
Notch signaling is enhanced 84. ErbB3 receptor was upregulated, which increased the effectiveness
of NRG1 signaling, suggesting the underlying mechanism may involve neuregulin. Together, these
data suggest that Notching signaling help drives SCP towards SC phenotype. After injuries, Notch
is upregulated to drive dedifferentiation of myelinating cells 84. After most SCPs have converted
into immature SCs, they start to envelop groups of axons, forming axon-SC columns85. SC
proliferation and death match axon and SC numbers. Radial sorting also starts at this time,
involving single axons segregating from the axon/Schwann cell families to become individually
ensheathed by a Schwann cell. This is a precondition for myelination, which subsequently takes
place in the case of larger axons.
SC generation is also subject to negative regulation. Endothelin has been shown to delay
the appearance of immature SCs from SCPs in vitro86. In vivo inactivation of endothelin B
receptors results in the premature appearance of immature SCs. These results suggest endothelin
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acts as a negative regulator of SC generations. The transcription factor AP2a in SCPs has also been
shown to play a role in the conversion of precursors to SCs 87. Whereas AP2a is highly expressed
in SCPs, its expression is dramatically decreased in immature SCs in vivo. This may suggest that
AP2a is involved in maintaining SCP phenotype and delay the generation of SCs.
After birth, immature SCs start to generate the two distinct populations of SCs: myelinating
SCs, and Remak cells. In uninjured nerves, Remak cells, or non-myelin SCs envelop all the smalldiameter axons, including small nociceptive (C-type) axons, the postganglionic sympathetic axons,
and the preganglionic sympathetic and parasympathetic fibers. In particular, many pre- and
postganglionic axons of the autonomic nerves are unmyelinated for their entire lengths. All PNS
nerves are unmyelinated for some portions of their axons and are surrounded by Remak cells. The
myelinating SCs are associated with larger diameter axons. Myelin sheath formed by SC
membranes can wrap multiple times around the axons resulting in insulated segments of nerve
bundles. Both Remak and myelinating SCs reside within the perineurium. SCs are surrounded by
a basal lamina, which is encased in the endoneurium with connective tissue, fibroblast, and blood
vessels. The perineurium contains multiple endoneuriums, and the epineurium contains multiple
perineuriums. Remak cells and myelinating SCs express distinct molecular profiles from each
other based on their functions. Markers, such as neural adhesion molecule (NCAM), L1 adhesion
molecules (L1CAM), p75 neurotrophin receptor (p75NTR), and glial fibrillary acidic protein
(GFAP) are expressed in Remak cells after development. In comparison, these markers are
significantly downregulated in myelin SCs after development

88

. Unique markers of the myelin

SCs are associated with its primary function of myelin formation. The transcription factor early
growth response 2 (ERG2/KROX20) is a major marker of myelin SCs, along with myelin protein
zero (MPZ), myelin basic protein (MBP), and myelin-associated glycoprotein (MAG).
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1.3.2 Repair Schwann Cell Phenotype and Its Role in Regeneration
One of the most remarkable features of SCs is their plasticity after injury. Both myelin SCs
and Remak cells transform into repair-supportive SCs, which involves a series of molecular and
morphological changes. In particular, myelinating SCs de-differentiate, marked by the
downregulations of pro-myelin genes including Krox20, MPZ, MBP, MAG, and periaxin.
Conversely, markers from immature SCs are re-expressed, including NCAM, p75NTR, GFAP,
and L1 which were downregulated before birth

89–92

. The de-differentiation of SCs may suggest

that repair-supportive SCs are similar to immature SCs. However, repair SCs show a unique
molecular expression profile marked by the expression of GDNF, oligodendrocyte transcription
factor 1 (Olig1), sonic hedgehog (Shh), and artemin

26,93

. These markers, with the exception of

GDNF, are absent in immature SCs. In addition, repair SCs activate a set of repair-related genes,
some of which are de novo. To promote neuron survival and axon regeneration, SCs release
neurotrophic factors, such as GDNF, artemin, BDNF, NT-3, NGF, VEGF, erythropoietin, FGFs,
pleiotrophin, and N-cadherin 26,27,94.
One of the key roles of SCs during injury is their ability to clear myelin. SCs have the
ability to breakdown myelin themselves and also recruit macrophages to degrade myelin debris.
During the first seven days after injury, about 50% of the myelin is degraded primarily by SCs 95.
This mechanism is important because myelin could inhibit axon growth

96,97

internalization, myelin is delivered to SC lysosomes for degradation

98

. Following myelin

. Cytokines, such as

interleukin-6 (Il-6) and leukemia inhibitory factor (LIF) are leased by SCs, which will recruit
macrophages to the nerve 99. Macrophages are responsible for myelin clearance after SCs. Il-6 and
LIF have been shown to not only attract macrophages to the injured nerve but also act on neurons
to promote axon regeneration 100. In addition, recruited macrophages provide an additional source
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of cytokines and promote vascularization of the distal nerve

95,101,102

. Morphologically, SCs

undergo elongation and branching. It was shown that four weeks after injury, Remak cells
increased their length by three-fold and myelin SCs doubled in length

103

. In addition, the

branching of SC processes was observed lying parallel to the main axis of the cell. The elongated
SCs align in columns (bands of Bungner) inside the basal lamina tubes that previously enclosed
myelin and axons before injury. This structure provides essential structural support and substrate
for regenerating axons to reconnect with end target organs.
Among the thousands of genes that are upregulated or downregulated, the upregulation of
c-Jun plays a crucial role in SC injury response. c-Jun is activated within hours of injury and
continue to increase for at least 7-10 days 103. Knockout of c-Jun in SCs significantly compromised
axon regeneration and functional recovery after sciatic nerve injury in mice 93. In comparison, the
development of SCs and nerve function in uninjured adult mice were normal. This highlight the
specific expression of c-Jun during injury. With a total of approximately 4000 genes that were
differentially expressed in SCs after injury, c-Jun knockout affected at least 172 genes. Among
these genes, Krox20, the master regulator of myelination was no-longer downregulated, along with
MPZ and MBP

93,104

. Therefore c-Jun plays a key role in helping to suppress myelin gene

expression in adult nerves after injury. c-Jun is also responsible for regulating the expression of
growth-promoting trophic factors. c-Jun knockout SCs failed to upregulate GDNF, artemin and
BDNF, p75NTR and N-cadherin. The knockout is believed to cause more sensory neuron death in
addition to initial death caused by injury 26,93. In addition to these functions, c-Jun is also believed
to affect the formation of the bands of Bungner. c-Jun knockout SCs tend to be flat and sheetforming in vitro and form a disorganized structure in vivo after injury

93

. Recent evidence also

suggests that reduced c-Jun activation is implicated in the age-dependent reduction in regeneration
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in older animals 105. Together, these findings demonstrate the importance of c-Jun expression for
SC injury response.

1.4 Glial-cell Line Derived Neurotrophic Factor (GDNF)
Glial cell line-derived neurotrophic factor was originally isolated from a rat glioma cell-line
as a trophic factor for the midbrain dopamine neurons. It was first found that GDNF protects
dopamine neurons in animal models of Parkinson’ disease

106–109

. It was also found that GDNF

was involved in motor neuron survival 110. Subsequently, GDNF has attracted a lot of attention as
a potential therapeutic agent to treat neurodegenerative diseases and trauma. In addition, GDNF
has important roles in other organ systems, acting as a morphogen in kidney development and
regulating differentiation of spermatogonia. Ret is a single-pass transmembrane protein that
contains four cadherin-like repeats in the extracellular domain and a typical intracellular tyrosine
kinase domain. It was identified as a signaling receptor for GDNF. However, their interaction was
of low affinity and an auxiliary ligand-binding subunit, GDNF family receptor alpha 1 (GFRα1),
was identified to have high affinity with GDNF 111,112. GFRα1 is anchored to the plasma membrane
through glycosylphosphatidylinositol (GPI) anchor and does not have an intracellular domain that
signals downstream pathways. Rather, it forms a complex with GDNF, which then acquires a high
affinity for Ret

113

. The GDNF/GFRα1/Ret complex can then activate downstream signaling

pathways, including Ras/MAP kinase and PI3K/AKT 114. GDNF activation of the PI3K pathway
is likely contributing to the neuroprotective effect of GDNF, demonstrated by the inhibition of
PI3K resulted in poor motor neuron survival 115. Chen et al. demonstrated that survival of sensory
and motor neurons was significantly increased by intramuscular injection of GDNF. GDNF also
had the most powerful effect on neurite outgrowth and elongation of sensory neuron and motor
neurons compared to NGF or CNTF injections 116. Multiple studies also demonstrated that GDNF
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delivery to injured nerves could enhance functional motor recovery 117,118. Another effect observed
with subcutaneous injections of GDNF or transgenic overexpression of GDNF in skeletal muscle
was hyperinnervation of neuromuscular junctions with abnormal motor endplates

119,120

. This

hyperinnervation seems to counteract synapse elimination, which involves the withdrawal of the
presynaptic terminal and the fine-tuning individual synaptic contacts for robust neuronal circuitry.
Together, these findings suggest that GDNF offers neuron protection during the early stages of
injury, promotes axon regeneration during the repair phase, and is involved in synapse formation
and reinnervation of end target organs.
In addition to its effects on neurons, GDNF also showed important functions in regulating
SC behavior. While GDNF signals through Ret in neurons, NCAM is likely the receptor of GDNF
in SCs, along with GFRα1 as co-receptor 121. Combined with GFR α1 and NCAM, GDNF activates
Fyn, a Src family kinase, which leads to activation of the Ras-Raf and Erk1/2 pathway. This
pathway regulates GDNF production by SCs, causing a positive feedback loop 122,123. In addition,
GDNF can affect SC proliferation and differentiation. Hoke et al. demonstrated that exogenous
GDNF increased SC proliferation and induced SC myelinating phenotype of normally
unmyelinated axons

124

. Findings from our lab showed that treatment of SCs with exogenous

GDNF upregulates the maturation marker S100β

123

. In addition, GDNF treatment appeared to

drive motor and sensory-derived SCs into their native phenotypes, which had become dysregulated
with time in culture125. Sensory SC markers, such as MBP and BDNF, are significantly upregulated
in sensory-derived SCs after GDNF treatment. Similarly, motor-derived SC markers protein kinase
C iota (PRKCi) and VEGF are increased in motor-derived SCs. One of the drawbacks of using
sensory-derived nerve graft, such as the sural nerve, to repair injured motor branches is that the
phenotypic differences can impair recovery

46

. By pre-conditioning either motor- or sensory-
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derived SCs with GDNF, our lab demonstrated that neurite extension was greatly improved in
mismatch pairs of neuron and SCs to similar lengths as matched pairs 126.

1.4.1 The “Candy-Store” Effect
Studies have shown that neurotrophic factors have a very short half-life and are cleared from
the body within hours

127

. Tissue penetration by diffusion is also limited

128

. Therefore, to

efficiently deliver GDNF as therapeutics, we must ensure a sustained release of biologically active
GDNF throughout the injury site, especially for long injury gaps. While many different delivery
methods have been developed, gene therapy has shown promise in treating PNI by using lentiviralmediated means 6,129,130. However, one of the major drawbacks of using GDNF to improve axon
regeneration is that overexpression of GDNF can cause the “candy-store” effect 8. Axons are
entrapped at the site of GDNF overexpression, and dramatic morphological changes occur in both
axons and SCs. This effect was first described by Blits et al. where adeno-associated viral vectormediated expressions of BDNF or GDNF were used to improve motor neuron survival after spinal
ventral root avulsions in rats 8. Both BDNF and GDNF overexpression significantly increased the
number of motor neurons after injury compared to sham groups. However, analysis of the number
of nerve fibers extending into the sciatic nerve for both groups were not significantly different
from all other groups. In particular, GDNF-induced fiber arborization and clusters were denser at
four months than that for BDNF. Using a rat sciatic nerve injury model, Santosa et al. demonstrated
that GDNF overexpressing SCs increased the number of nerve fibers to a similar level as isograft
in the midline of ANA 7. However, this number was dramatically decreased in the distal region of
the graft. Neural tissue and nerve fiber width were also significantly less than all other groups,
including ANA only. Functional recovery measured by muscle force was also worse with GDNF
overexpressing SCs than isograft and wildtype SCs with ANA. To bypass the negative impact of
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GDNF, Eggers et al. attempted to establish a gradient of GDNF expression by injecting increasing
dosages of lentiviral vectors with GDNF overexpression in rat sciatic nerve 130. The “candy-store”
effect was observed even with the lowest dosage of GDNF lentiviral vectors. Similar to previous
studies, axons form densely pack fiber networks presented as nerve coils in vivo 131,132. SC number
also dramatically increased at the site of GDNF overexpression. Importantly, strong p75NTR
immunoreactivity was detected, indicating the presence of immature and non-myelinating SCs. At
the same time, MBP expression was decreased, and thin myelin sheath was observed. These data
suggest that GDNF overexpression not only induce axon entrapment but also profoundly affect
SCs morphology. Whereas moderate levels (100ng/mL) of GDNF seem to increase the expression
of MBP in sensory-derived SCs, GDNF overexpression reversed such an effect 123,130.
While the exact mechanism of how GDNF causes the “candy-store” effect is unknown, our
lab has previously demonstrated that temporal control of GDNF overexpression can improve
regeneration while avoiding axon entrapment 6. In a rat sciatic nerve injury model, a 3 cm injury
gap was bridged by ANA containing GDNF-releasing fibrin scaffold. Tetracycline-inducible (TetOn) GDNF overexpressing SCs were transplanted into the distal nerve to encourage growth past
the ANA. It was determined that the tetracycline-induced GDNF expression for 6 weeks enabled
axons to cross the 3 cm injury gap. The total number of axons detected in the distal nerve was
comparable to isograft. In contrast, 4 weeks of expression was insufficient for regeneration, while
8 weeks resulted in axon entrapment. Both groups showed a significantly lower number of axons
in midgraft and the distal nerve compared to isograft and 6 weeks of doxycycline treatment. In
addition, 6 weeks of doxycycline treatment resulted in decreased myelin debris both in midgraft
and the distal nerve. Gastrocnemius and tibialis anterior muscle mass were similar to that of the
isograft group and significantly higher than all other groups. This study demonstrated that the
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temporal and spatial control of GDNF release might play a major role in causing the “candy-store”
effect. Normal doxycycline-inducible system in preclinical studies showed loss of transduced cells
caused by an immune response to the foreign transactivator in rodents and non-human primates
133–137

. A recent study used an immune-evasive doxycycline-inducible gene switch to control

GDNF expression in avulsed reimplanted ventral spinal roots

138

. GDNF expression was either

constitutively on or turned on for 1 month. Both groups with GDNF expression were able to
improve motor neuron survival. However, retrograde tracing from the sciatic nerve (10cm distal
from the implantation site) showed a higher number of labeled motor neuron with 1 month of
GDNF expression than all other groups, including constitutive GDNF expression. The number of
fibers observed in the sciatic nerve was also the highest. Functional recovery, measured by
compound muscle action potential of the gastrocnemius and plantar muscle, was better with the 1
month of GDNF expression 24 weeks post-repair. This study again showed that the controlled
release of GDNF could significantly impact axon entrapment. As previously mentioned, the
mechanism by which GDNF causes the “candy-store” effect is still unknown. Understanding this
mechanism can help us develop GDNF delivery strategies that reduce axon entrapment.

1.5 Concluding Remarks
In this body of work, we aim to study the underlying mechanism by which GDNF causes
the “candy-store” effect. All previous studies that demonstrated axon entrapment were in vivo.
However, given the complexity of the in vivo environment and the involvement of multiple cell
types in the PNS, it can be difficult to study and understand individual components and factors
that cause axon entrapment. Here we want to develop an in vitro culture platform using a
microfluidic device that enables clear visualizations of axon extensions under various conditions
that could cause axon entrapment. In addition, we wish to explore how GDNF impact SCs and
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neuron individually. By understanding the underlying mechanisms of how GDNF causes axon
entrapment, we can better develop drug delivery methods that harness only the beneficial effects
of GDNF while reducing the negative impacts.

Chapter 2: A microfluidic platform to study
the effects of GDNF on neuronal axon
entrapment
2.1 Abstract
One potential treatment strategy to enhance axon regeneration is transplanting Schwann
Cells (SCs) that overexpress glial cell line-derived neurotrophic factor (GDNF). Unfortunately,
constitutive GDNF overexpression in vivo can result in failure of regenerating axons to extend
beyond the GDNF source, a phenomenon termed the “candy-store” effect. Little is known about
the mechanism of this axon entrapment in vivo. We present a reproducible in vitro culture platform
using a microfluidic device to model axon entrapment and investigate mechanisms by which
GDNF causes axon entrapment. The device is comprised of three culture chambers connected by
two sets of microchannels, which prevent cell soma from moving between chambers but allow
neurites to grow between chambers. Neurons from dorsal root ganglia were seeded in one end
chamber while the effect of different conditions in the other two chambers was used to study
neurite entrapment. The results showed that GDNF-overexpressing SCs (G-SCs) can induce axon
entrapment in vitro. We also found that while physiological levels of GDNF (100 ng/mL)
promoted neurite extension, supra-physiological levels of GDNF (700 ng/mL) induced axon
entrapment. All previous work related to the “candy-store” effect were done in vivo. Here, we
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report the first in vitro platform that can recapitulate the axonal entrapment and investigate the
mechanism of the phenomenon. This platform facilitates investigation of the “candy-store” effect
and shows the effects of high GDNF concentrations on neurite outgrowth.

2.2 Introduction
Severe peripheral nerve injury (PNI) can have a devastating impact on patients’ quality of
life resulting in lifelong disabilities. Autologous nerve grafting has been the standard of care for
PNI, despite its major disadvantage of donor site morbidity18. Alternative methods, such as
acellular nerve grafts, are ineffective for large gaps because of the lack of cells and regenerative
factors within the graft139. Even with proper surgical reconstruction, functional recovery can be
incomplete140. Although the peripheral nerve is capable of regeneration, the rate of axonal
regeneration is slow at 1-2 mm/day2. Patients suffering from proximal injuries, such as brachial
plexus injuries, which can involve regeneration distances of up to a meter, may require 2-3 years
for axons to reach target muscles18. However, chronic denervation can result in quiescence of
Schwann cells (SCs), which leads to their precipitous decline in growth factor expression and a
progressive failure to promote axonal regeneration over time139. In addition, essentially irreversible
changes to muscle occur by 12-18 months141, at which point functional recovery is unlikely. To
treat these patients, it is critical to devise strategies to enhance axonal growth and prevent chronic
denervation of SCs to promote robust axon regeneration over long distances. One appealing
strategy to improve recovery is to use exogenous growth factors and/or SCs with exogenous
growth factor expression to enhance axonal regeneration.
Glial cell line-derived neurotrophic factor (GDNF) is one of these potent growth factors
involved in the normal regenerative process after injury. GDNF has been shown to improve axonal
regeneration in motor neurons4 and a subset of sensory neurons5. In vitro studies have shown that
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GDNF forms a complex with GDNF family receptor alpha 1 (GFRα1) and acts as an axonal
guidance signal during regeneration6,8,10,11. Although SCs intrinsically secrete GDNF following
injury, they are unable to maintain this trophic support for neurons over long periods of time after
injury30. In rodents, injury-induced GDNF expression is insufficient to stimulate axonal
regeneration after 2 months and decreases to baseline level by 6 months30. Therefore, one viable
strategy to increase the regeneration window is to develop effective delivery systems for GDNF
over a long period of time.
Various methods of delivery have been developed including protein delivery systems, gene
therapy, and cell therapy. In particular, the use of adeno-associated and lenti-viral vectors that
encode GDNF have been used in many studies. Our lab and others have previously studied
lentiviral mediated overexpression of GDNF from SCs (GDNF-overexpression SCs, or GSCs)5,6,8,130. However, excess GDNF production causes the “candy-store” effect, where axons do
not extend beyond sources of GDNF
expression and are entrapped at a site rich
in growth factor8,9,130 (Fig. 2.1). Axonal
swirling and coils form at these GDNF
sources and are composed of a large
number of motor axons and densely
packed SCs9,130. Inside the axon coils,
myelination is severely impaired as shown
Figure 2.1: Schematics of the Candy-Store
Effect. Axons normal grow past Schwann cells
(SC) and reach towards target muscles (Top). When
we constitutively overexpress GDNF in SCs
(GDNF-SC), axons fail to extend beyond the
GDNF source (Bottom), causing the Candy-store
effect
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by a decrease in myelin basic protein
expression130. These negative side effects
create a major barrier against using GDNF

to promote axonal regeneration. Understanding the “candy-store” effect is important for
effectively using GDNF to promote axonal regeneration and reduce its negative impact. Studying
the “candy-store” effect in vivo is challenging given the involvement of multiple cell types and the
complex peripheral nerve environment. In contrast, in vitro investigation will enable us to conduct
controlled studies of individual factors. However, standard in vitro culture platforms cannot
spatially separate neurons from extending neurites for clear visualization. Alternatively,
microfluidic devices have been extensively used to model nerve injury126,142–145, with the major
advantage of easy fabrication of the topographical structures of the culture platform. Namely,
microfluidic devices can have features on the micrometer scale, which is ideal for isolating neurite
extensions from neuronal soma. Therefore, developing a microfluidic device for recapitulating
axon entrapment will allow for investigating the mechanism of the “candy-store” effect.
In this study, we developed a microfluidic device to recapitulate the “candy-store” effect
in vitro and examined the effects of G-SCs on neuronal axon entrapment. Neurite extension was
quantified in neuron-SCs (normal SCs) and neuron-G-SCs (GDNF overexpressing) co-cultures.
We also investigated the effects of different GDNF concentrations on axon entrapment. G-SCs
resulted in significantly greater trapping compared to normal SCs indicating that G-SCs can entrap
neurites in vitro. In addition, high GDNF concentrations led to a similar decrease in neurite
extension suggesting that high GDNF levels alone are sufficient to entrap axons.

2.3 Materials and Methods
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2.3.1 Fabrication of Microfluidic Device Master Mold
3-inch silicon wafers (Silicon Inc. ID, USA) were coated with SU-8 5 photoresists
(MicroChem Corp, MA, USA) using a spin-coater. The wafers were then exposed under UV light
under (or through) the first layer of photo mask that had the pattern for the microchannels (Fig.
2.2). After development, the wafers were coated with a layer of SU-8 2050 and exposed under the
second photo mask, which contained the pattern for the cell culture chambers. After development,
the wafers were exposed to trichloro(1,1,2,2-perfluorooctyl) silane (Millipore Sigma, MO, USA)
under vacuum for 1 hour to form an antiadhesive layer.

Figure 2.2: Schematics of Microfludic Device Fabrication Process. The master mold for the
device consist of two layers of photoresist structures. The first layer defines the microchannels
at 5 μm height. The second layer defines the culture chambers at 100 µm height. Soft
lithography is used to make PDMS device, which is then assembled with glass coverslip as
bottom and coated with PLO-laminin. The three chambers are connected by two sets of
microchannels. The middle chamber is accessed through the two circular reservoirs.
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2.3.2 Soft Lithography and Microfluidic Device
Polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, MI, USA) was poured onto the
silicon master mold in a petri dish with 1:10 weight ratio of curing agent to base and put under
vacuum to remove air bubbles (Fig. 2.2). The PDMS was cured at 60°C overnight. The device was
then cut out and bonded to a glass slide using a plasma cleaner (Plasma Clean PDC-001, Harrick
Plasma Inc., NY, USA). After 20 minutes of UV sterilization, the completed device was coated
with 0.01% poly-L-ornithine (PLO) for 1 hour at 37°C and laminin (1 mg/mL, Life Technologies,
CA. USA) for 1 hour at 37°C.

2.3.3 FITC Conjugation and Protein Transport Quantifications
Fluorescein isothiocyanate (FITC) conjugation was performed as directed by the
manufacturer (Sigma). Porcine pepsin (35 kD, Sigma) was used as an alternative to GDNF (30.4
kD) for protein labeling because of their similar sizes. After completion of the conjugation, the
FITC-labeled protein was in PBS solution with 1% bovine serum albumin (Sigma). Various
volumes of FITC-labeled protein (1 µg/mL) in solution were then applied to the distal chamber
with the expectation that higher volumes would increase protein transport to the somal chamber.
After 24 hrs, the liquid from the somal chamber was collected and the fluorescence was measured
at 488nm using a fluorescence spectrophotometer (SpectraMax M2e, Molecular Devices, CA,
USA). The percent fluorescence was calculated as a percentage of somal chamber fluorescence
intensity over distal chamber fluorescence intensity.
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2.3.4 Isolation of Sensory Neurons and Culture Conditions
Sensory neurons were harvested from White Leghorn chicken (Texas A&M University,
Texas, USA) embryos at Day 7-9. Dorsal root ganglia were isolated from embryos and dissociated
using 0.25% trypsin-EDTA (Invitrogen, CA, USA) for 20 minutes at 37°C. Dissociated neurons
were seeded in the somal chamber at 85,000 cells/cm2 and cultured in neurobasal medium with 2%
B27 supplement, 1% penicillin-streptomycin (Pen/Strep), and 1% GlutaMAX (Invitrogen) (Fig.
2.3). Glial cell-line derived neurotrophic factor (GDNF, PeproTech, NJ, USA) was applied to the
middle and/or distal chamber. Medium in the somal chamber was replaced with fresh medium
every two days. Medium in the middle and distal chamber was also replaced every two days to
maintain the GDNF level. By replacing media every two days in all chambers, the volumes of each
chamber was maintained.

Figure 2.3: Schematics of the microfluidic device. A) Top and B) side views of the
microfluidic device. Both Somal and Distal chambers have a surface of 10 mm×3 mm
(schematics are not drawn to scale). Middle chamber reservoirs are 5mm in diameter and the
chamber dimensions are 100 mm × 200 μm × 100 μm (L×W×H). The two sets of microchannels
dimensions are 5 × 5 × 500 (L×W×H) μm. Side view shows different volumes applied to each
chamber. The volume applied to the middle chamber is the volume applied to the two circular
reservoirs.
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2.3.5 Schwann Cell Harvest and Culture
SCs were harvested from sciatic nerves collected from adult male Lewis rats using
previously described methods146. To isolate the SCs, first nerve branches were placed in DMEM
(Dulbecco's Modified Eagle Medium) with sodium pyruvate (110 mg/L, Invitrogen), Collagenase
(10 mg/mL, Thermo Fisher), and 0.25% trypsin for 30 min at 37 °C. After triturating the branches,
they were centrifuged for 10 min at 500×g, and the cell pellet was washed with SC medium
containing DMEM plus 10% fetal bovine serum (FBS, Life Technologies) and 1% Pen/Strep. The
cells were then plated into a 100 mm petri dish coated with 0.1% poly-L-lysine (Sigma) and
laminin. Cytarabine (Ara-C, 10 μM, Sigma) was added to the plate along with fresh SC medium
on Day 3 after plating. Then the plate was supplemented with 2 μM forskolin (BioGems, CA, USA)
with fresh SC medium and cultured for 1-2 weeks before use. G-SCs were generated based on a
protocol previously developed 5. Briefly, SC cultures were transduced with lentiviral particles
containing GDNF transfer plasmid before passage 7. Cells were incubated with 2 μg/mL of
polybrene (Santa Cruz Biotechnology, TX, USA) in SC medium for 1 hour at 37°C, after which
the lentiviral vectors containing GDNF are introduced (MOI = 35). Cells are then incubated with
2 μg/mL polybrene and vector for 20 hours at 37°C. G-SCs were tested using enzyme-linked
immune-sorbent assay (ELISA, R&D Systems, MN, USA) for GDNF production according to
previously published results 5. G-SCs were seeded in the middle chamber at 100,000 cells/cm2. GSCs produced 106.2±6.8 ng/mL/day of GDNF in the middle chamber. Based on this GDNF
production, approximately 744 ng/mL of GDNF was produced over 7 days. Therefore, we used
700 ng/mL of GDNF as the supra-physiological level to be applied in the middle chamber.
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2.3.6 Immunocytochemistry and Data Quantification
Immunocytochemistry (ICC) was performed on Day 6 after the start of neuronal culture.
Briefly, the cells in the device were fixed using 4% paraformaldehyde (Sigma) for 20 min. After
washing 3 times with PBS, the cells were permeabilized with 0.01% Triton X-100 (Sigma) for 20
min. The cells in the device were then blocked using 5% normal goat serum (NGS, Sigma) in PBS
for 1 hr. Primary antibodies used included anti-neurofilament (1:200 with 2% NGS in PBS, clone
3A10, Developmental Studies Hybridoma Bank, IA, USA) for neurites and anti-S100β (1:400 with
2% NGS in PBS, Polyclonal Rabbit Ant-S100, Dako, CA, USA) for SCs. After incubating with
primary antibodies overnight, the device was washed 3 times with PBS and then secondary
antibodies were applied for 2 hrs. Hoechst 33342 was applied (1:1000 dilution) for 20 min after
washing the device with PBS. The device was then imaged using a wide-field fluorescence
microscope (Leica DMi8, Leica, IL, USA). After acquiring images of the middle chamber and
microchannels, neurites were quantified as a percentage of axons crossing, namely, the number of
neurites exiting the middle chamber was divided by the number of neurites entering the middle
chamber (Fig. 2.5). Overlapping neurites in one microchannel are accounted for by tracing them
for a short distance after exiting the microchannel, at which point the neurites disperse (typically
3-4 neurites, data not shown).

2.3.7 Statistical Analysis
One-way ANOVA is performed on the sample groups using Minitab software. Scheffe’s
post-hoc test with p<0.05 for significance was used. Data represented were shown as mean ±
standard deviation. Data included N = 8 or more devices per condition; n=30-518 neurites
measured per device.
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2.4 Results
2.4.1 Microfluidic device development
One of the key features in the design of this microfluidic device was that it should enable
cell signaling through exogenous growth factors and/or cell-cell interactions. Therefore, it was
important to test protein transport from distal chamber to somal chamber in the microfluidic device
to ensure that factors in the distal chamber could elicit a response in neurons separated by
microchannels. We also sought to determine whether a growth factor in the distal chamber could
provide axon guidance and/or promote survival of neurons seeded in the other chamber. We used
pepsin (35 kDa), a similarly sized protein to GDNF (30.4 kDa), conjugated with fluorescein
isothiocyanate (FITC) to examine the transport of proteins between the distal and somal chamber.
FITC-pepsin was applied to the distal chamber and the fluorescence intensity in the somal chamber
was measured over time. This allowed an estimation for the amount of GDNF that will reach the
somal chamber for neurons to detect, and thus was used to determine the initial GDNF
concentration that should be applied to the distal chamber to obtain a physiologically relevant level
in the somal chamber.
We tested whether protein transport can be controlled by modulating the volume in each
chamber (and thus the pressure differential) such that fluid was only flowing unidirectionally from
the distal to the somal chamber. Two different volume sets were applied to the device. The first
set of conditions tested had 50 µL of liquid in the somal and the middle chamber, and 100 µL of
liquid in the distal chamber (Fig. 2.4A, 50/50/100). After 24 hours, the fluorescence intensity in
the somal chamber was 6.6±2.0% of the initial fluorescence intensity in the distal chamber. The
second set of conditions had 110 µL of liquid in the middle chamber, and 170 µL in the distal
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chamber.

The

increased

to

fluorescence
13.8±3.0%

(Fig.

intensity
2.4A,

50/110/170). This demonstrated that protein
concentration in the somal chamber can be
controlled by varying the volume applied to
the other two chambers.
To

test

whether

high

GDNF

concentrations can cause axon entrapment in
vitro, we wanted to first establish a positive
control that allows neurites to robustly cross
the middle chamber. Table 2.1 shows the
conditions applied to the middle and distal
chambers. Either no GDNF, 100ng/mL, or
700ng/mL of GDNF was added to the
respective chambers. No growth factor
Figure 2.4: Microfluidic device shows
controlled protein transport and robust axon
crossing. A) Varying the loading volume in
each chamber changes the amount of protein
transported. 50/50/110 correspond to the
volumes in somal/middle/distal chamber in μL.
With a volume increase in the distal and middle
chamber, the amount of fluorescence increased
more than 2-fold (6.6% to 13.8%). *: p<0.05
N=4. B) Quantification of axons crossing the
middle chamber with different conditions. Both
conditions showed robust axons crossing (/G100
at
64.6%±10.7%,
-/G700
at
55.3%±15.2%). N = 8.

addition resulted in low neurite outgrowth
into

the

middle

chamber
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neurites/device). Even though the percentage
of axon crossing was low under this condition,
it did not represent the axonal entrapment
effect but likely a result of poor neurite
extension in the first place. We found that
with 100 ng/mL and 700 ng/mL of GDNF in
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the distal chamber and 0 ng/mL in the middle and somal chamber, neurites were able to robustly
grow across the middle chamber to reach the second set of microchannels (Fig. 2.4B). Both
conditions showed at least 50% of axons crossing with an average of 261 neurites measured in
each device. These two conditions were used positive controls to compare with potential axon
trapping conditions.

2.4.2 GDNF-overexpressing Schwann cells show axon entrapment in the
microfluidic device
To mimic the in vivo axon entrapment in the microfluidic device, we evaluated the effects
of placing G-SCs in the middle chamber, on neurite outgrowth compared to normal Schwan cells
(Table 2.1). Briefly, we seeded DRG neurons in the somal chamber and normal SCs or G-SCs in
the middle chamber (Fig. 2.5). We found that seeding normal SCs in the middle chamber resulted
in robust axon growth resulting 59.2% axons crossing (Fig. 2.6C, SC/-), comparable to 100 ng/mL
of GDNF in the distal chamber (Fig. 2.4B). In contrast, seeding G-SCs in the middle chamber
significantly reduced the percentage of axons crossing to the distal chamber to 25.3% (Fig. 2.6C,

Figure 2.5: Schematics of culturing conditions. Neurons are seeded on Day 0 and stained on Day 7
using immunocytochemistry (ICC), at which point the percentage of axons crossing is quantified.
Different Schwann cells or GDNF concentrations are applied to the middle chamber and distal chamber
(Table 2.1).
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G-SC/-). These results demonstrated that G-SCs can induce axon entrapment in vitro. It was also
noted that neurites with G-SCs seeded in the middle chamber formed a dense network of fibers
along the G-SCs (Fig. 2.6B), while neurites with normal SCs do not demonstrate this behavior
(Fig. 2.6A). This resembled morphologies observed in previous in vivo studies where axons tend
to form nerve coils at the sites of GDNF overexpression8,130.

Figure 2.6: GDNF-Overexpressing Schwann Cells causes axonal trapping in vitro. A-B)
Normal Schwann Cells (A) and G-SCs (B) seeded in the middle chamber. C) Quantification of
axons crossing. SC results in 59.2±12.3%. G-SC results in 25.3±9.9%. N=8. *: p<0.00005
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Table 2.1
List of conditions applied to the middle and distal chambers
MIDDLE CHAMBER

DISTAL CHAMBER

SCHWANN CELLS

None

GDNF-OVEREXPRESSING

None

SCHWANN CELLS
CONTROL (NO GDNF)

None

GDNF (100ng/mL)

GDNF (700ng/mL)

GDNF (100 NG/ML)

None

GDNF (100ng/mL)

GDNF (700ng/mL)

GDNF (700 NG/ML)

None

GDNF (100ng/mL)

GDNF (700ng/mL)

2.4.3 Effects of differential GDNF concentrations on neurite extensions
We wanted to examine the effects of different concentrations of GDNF in the middle and
distal chambers (Table 2.1). Previous in vitro studies had shown that physiological levels of GDNF
(100 ng/mL) improve neurite outgrowth126. In addition, applying 100 ng/mL of GDNF to the distal
chamber also promoted robust neurite outgrowth towards the distal chamber. Based on the GDNF
production from G-SCs, approximately 744 ng/mL of GDNF was produced over 7 days. Therefore,
we used 700 ng/mL of GDNF as the supra-physiological level. GDNF uptake by neurons was
qualitatively assessed by ICC staining of GDNF. Cell treated with 700ng/mL of GDNF showed
greater levels of antibody staining compared to untreated cells and cell treated with 100ng/mL of
GDNF (Fig. 2.7). We found that supra-physiological levels of GDNF in the middle chamber
significantly reduced the percentage of axons crossing the middle chamber (Fig. 2.8G). Applying
100 ng/mL of GDNF to the middle chamber with 700 ng/mL in the distal chamber did not reduce
the percentage of axons crossing comparing to 100 ng/mL in the distal chamber and 0 ng/mL in
the middle chamber (Fig. 2.8G, -/G100, G100/-). However, 700 ng/mL of GDNF in the middle
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chamber and 0 ng/mL in the distal chamber significantly reduced the percentage of axons crossing
to 14.0% (Fig. 2.8D & G, G700/-). This suggests supra-physiological levels of GDNF can induce
axon trapping in vitro. Immunostaining for neurofilament showed that neurites tend to stay in the
middle chamber; however, we did not observe the formation of dense fibers networks observed
with G-SCs. We also examined the effects of GDNF at 250 ng/mL and 500 ng/mL applied in the
middle chamber and 0 ng/mL in the distal chamber (G250/-, G500/-). G250/- showed axons
crossing at 40.6%±12.4%; while G500/- showed axons crossing at 45.8%±15.3%. This indicates
the threshold concentration for GDNF to induce axon entrapment appears to be between 500
ng/mL and 700 ng/mL.

Figure 2.7: Immunocytochemistry of GDNF Uptake by the Dissociated DRGs. Dissociated DRGs
are cultured in 48-well plates and immunostained with GDNF- and neurofilament-antibodies. A-B)
Untreated and 100ng/mL of GDNF treated cell cultures showed relatively weak GDNF fluorescent
signals. Untreated condition showed some signals likely because of the SCs present in the dissociate
DRG cultures. SCs are known to secrete GDNF in cell culture 197. C) Dissociated DRGs treated with
700ng/mL of GDNF showed stronger fluorescent signals compared to the other groups. D-F) Merged
image of GDNF with Neurofilament and Hoechst nuclear stain.
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Next, we wanted to see whether adding GDNF to the distal chamber can overcome the
axon trapping induced by applying high levels GDNF to the middle chamber (Fig. 2.8H). When
100 ng/mL of GDNF was in both middle and distal chambers, 54.8% of axons were able to cross
the middle chamber, similar the result observed with the same concentration of GDNF added to
either just the distal or just the middle chamber (Fig. 2.8B, G100/G100). This suggests that axons
were not trapped by a uniform distribution of GDNF at a physiological concentration. In contrast,
applying supra-physiological levels of GDNF in the middle chamber and physiological GDNF
levels to the distal chamber reduced the percentage of axons crossing to 24.3% (Fig. 2.8E & H,
G700/G100). Therefore, physiological GDNF levels at a more distal site to the neurons cannot
overcome axon trapping induced by high GDNF levels at a more proximal site. More importantly,
when supra-physiological GDNF is applied to both the middle and distal chambers, only 14.1% of
axons were able to cross the middle chamber (Fig. 2.8F & I, G700/G700), suggesting that high
GDNF levels also cannot abolish axon trapping. Together, these data suggest that supraphysiological levels of GDNF have a direct effect on reducing neurite outgrowth.

2.5 Discussion
A number of studies have focused on the use of exogenous growth factors for treating
peripheral nerve injuries. Growth factors, such as GDNF, are released by SCs in response to nerve
injury and aid neuronal survival and axon regeneration3. Many studies have shown that GDNF
also acts as a directional cue for guidance of regenerating axons

147,148

. In addition to its direct

benefits, GDNF also contributes to the ability of SCs to promote repair after injury. The presence
of GDNF enhances the ability of SCs to myelinate axons by inducing differentiation of a
myelinating phenotype122–124. As a result of their growth promoting benefits, various methods for
the
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Figure 2.8: Effects of differential GDNF concentrations on neurite extensions. A-C) Low
(100ng/mL) GDNF applied to the middle chamber with varying concentrations in the distal
chamber. A) G100/- at 50.9±14.0%; B) G100/G100 at 54.8±17.0%; C) G100/G700 at 51.8±22.2%.
D-F) High (700ng/mL) GDNF applied to the middle chamber with varying concentrations in the
distal chamber. D) G700/- at 14.0±10.0%; E) G700/G100 at 24.3±10.7%; F) G700/G700 at
14.1±8.1%. G-I) Quantification of axons crossing with varying concentrations of GDNF applied
to the middle chamber and distal chamber. N=8. *: p<0.00005, **: p<0.05, ***: p<0.005.
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delivery of growth factors have been examined including using lentiviral9,149 or adenoviral
injections150, microspheres34,151, and scaffolds and conduits152. Yet, there still remains much to be
understood about the effects of growth factors on axon regeneration.
Unlike other growth factors153–155, GDNF when overexpressed can cause axon entrapment
within the zone of GDNF expression, and is thus dubbed the “candy-store” effect8,9,130,132,156. This
behavior was first shown by Blits et al., where adenoviral-mediated overexpression of GDNF near
the motoneuron pool promoted axon sprouting but prevented directional growth of axons at
denervated motoneuron pool. We and others have also observed a similar phenomenon when
overexpressing GDNF after sciatic nerve injury with either viral expression or transgenic
expression in SCs6,130. In order to resolve this issue, Eggers et al. generated a GDNF gradient in
vivo using lentiviral vectors and found that even the lowest concentration of GDNF still entrapped
axons. We and others have used tetracycline-inducible systems to temporally control GDNF
overexpression and identified a critical window of time at which GDNF overexpression should be
shut off

6,132

. However, little is known about the mechanism of the “candy-store” effect and

whether it acts directly on axons or indirectly via SCs. Evidence suggests SCs undergo phenotypic
changes in the presence of high levels of GDNF that could affect axon growth130. A recent study
also shows G-SCs affect fibroblasts, and this interaction results in significant ECM remodeling 156.
However, all these studies have been done using in vivo models. The complexity of the in vivo
environment presents a major challenge to eliciting the exact mechanism that underlies the “candystore” effect. Here we developed a microfluidic device that enables us to conduct controlled studies
of individual factors and provide spatial separation of neurons from extending neurites for clear
visualization. This in vitro culture platform can help us understand why GDNF overexpression
leads to the “candy-store” effect.
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Previous studies have shown that G-SCs cause axon entrapment when transplanted in
acellular nerve graft in sciatic nerve injury models6. Similarly, our results show that G-SCs cause
axon entrapment in the microfluidic device. This demonstrates that our in vitro platform is able to
mimic the in vivo phenomenon. Previous studies have shown that GDNF overexpression causes
SCs to undergo phenotypic changes marked by a decrease in myelin basic protein and an increase
in p75 receptor expression130. In this study, we observed that neurites form dense fiber networks
along G-SCs, whereas these dense fibers were not observed in the presence of normal SCs (Fig.
2.6A & B). This dense accumulation of axons is strikingly similar to previous in vivo results where
elevated GDNF expression from virally-induced cells resulted in thick fiber coils formed at GDNF
overexpressing locations8,130,156. Our recent study showed that GDNF overexpression during nerve
regeneration in vivo caused extensive axonal sprouting

156

. The evidence from these studies and

our current studies suggests G-SCs play a major role in causing axon entrapment. Specifically,
these cells can prevent neurites from extending beyond the region of elevated GDNF and induce
the formation of fiber networks. GDNF gradients can guide axon regeneration from lower
concentrations to higher concentrations and eventually lead to muscle cells as the final target in
the PNS. It has been shown that viral vector-induced GDNF expression in myoblasts improved
motor neuron survival

157

. Making myoblast as a source of neurotrophic factor would be

particularly useful when nerves were close enough to the muscles to create a gradient that the
axons could sense. Therefore, it might also be valuable to explore using myoblast as the source of
neurotrophic factor for future studies of regeneration near the muscle.
In addition to investigating G-SC’s effects on axon entrapment, we examined how
exogenous GDNF affects neurite outgrowth in a microfluidic device. Previous studies have shown
that GDNF applied at physiological levels (50 to 100 ng/mL) promoted axon growth 123,126. In this
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study, our results indicated that GDNF applied at a supra-physiological level (700 ng/ml)
decreased neurite outgrowth. This suggests that a high GDNF level may be sufficient to trap axons.
It is interesting to note that high GDNF levels in the distal chamber did not make up for axon
entrapment caused by high GDNF in the middle chamber, suggesting axon entrapment is activated
when GDNF reaches a certain threshold concentration and cannot be overcome by similarly high
levels downstream. We also observed that neurites treated with high GDNF protein levels did not
show dense fiber network formation. Compared to trapping caused by G-SCs, this might suggest
the important roles of G-SC and ECM remodeling in axon entrapment and that the “candy-store”
effect constitutes two parts, where axon trapping is caused by GDNF directly while fiber networks
form after ECM remodeling and may involve SCs.
Understanding both the benefits and negative impacts of using growth factors is critical
developing safe therapeutics. Here, we have developed a microfluidic platform that allowed us to
investigate a major negative side effect of overexpressing GDNF from SCs. We have shown that
G-SCs can induce axon entrapment similar to what is seen in vivo. In addition, this system allowed
us to examine the effect of exogenous GDNF on neurite outgrowth. We have shown that high
levels of GDNF alone can significantly reduce neurite outgrowth due to entrapment. Overall, this
platform may provide a valuable tool to further investigate the underlying molecular mechanisms
of the “candy-store” effect. Together, these findings may prove valuable as they provide directions
toward devising drug delivery methods that harness only the beneficial effects of GDNF to
establish a robust treatment system for PNI in animal models. Clinically, this project has the
potential to lead to therapies that prolong the regeneration window for long gap PNI.
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Chapter 3 Slitrk4 Activation by High GDNF
Levels Leads to Neuronal Axon Entrapment
3.1 Abstract
Glial cell line-derived neurotrophic factor (GDNF) is a potent growth factor that affects
both axon growth and the ability of Schwann cells (SC) to promote regeneration. Previous studies
have shown that GDNF release through lentiviral-mediated overexpression can result in a “candystore” effect, where the regenerating axons are entrapped and fail to extend beyond regions of high
transgenic GDNF. We previously developed an in vitro culture platform that enables us to model
the “candy-store” effect in vitro. In the current study, we used this platform to continue
investigating the effect of GDNF on SCs’ ability to promote axon regeneration and the underlying
mechanisms of how GDNF can promote axon entrapment. We found that GDNF-overexpressing
SCs (G-SCs) induced axon entrapment that cannot be overcome by high GDNF levels distally.
SCs pre-conditioned with high GDNF concentrations also can cause axon entrapment; however,
such pre-conditioned SCs cannot trap axons when high GDNF were present distally. After
analyzing neuron gene expression changes after high levels of GDNF treatment, we found that
SLIT and NTRK-like family member 4 (SLITRK4) was upregulated. Our results indicate that by
knocking down SLITRK4 expression using shRNA, axon entrapment was significantly reduced.
Furthermore, inhibition of SLITRK4 ligand, protein tyrosine phosphatase σ (PTPσ), with PTP IV
Inhibitor, a small molecule inhibitor, also significantly reduced axon entrapment. Our findings
may provide valuable insight for understanding the effects of GDNF on peripheral nerve
regeneration and contribute to developing better treatment strategies that harness the beneficial
effects of GDNF without entrapment.
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3.2 Introduction
Peripheral nerve injury (PNI) can severely impact patients’ quality of life. Proximal injuries
with a large gap between the two nerve ends are less likely to recover, as regenerating axons need
to travel long distances over an extended time to reconnect to the end-organ targets 1. Some of the
main contributing factors to poor functional recovery include motor neuron apoptosis with chronic
denervation and the decline of the growth-promoting capacity of Schwann cells (SC) 158–161. After
injury, SCs are known to de-differentiate and activate (alternative differentiation) to become
“repair phenotype” SCs 93. This process involves the downregulation of myelin-associated genes,
upregulation of trophic factors and surface proteins providing support for injured neurons and
substrates for growth cones, the formation of regeneration tracks for axon guidance, and activation
of cytokines and autophagy for myelin breakdown directly, and by macrophages

162

. Important

trophic factors and cell-surface proteins that support survival and axon growth include glial cell
line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and artemin,
neurotrophin receptor p75 (p75NTR) and N-cadherin 26,27,93,163–166 . In particular, GDNF has been
extensively studied for its effects on promoting axon regeneration, improving motor neuron
survival, and guiding proper axon reinnervation leading to enhanced motor output 30,117,148,167–169.
Equally important are the effects GDNF has on SCs after injury. GDNF is known to affect SC
maturation, migration, and proliferation 121,123,124,170–172.
Although exogenous GDNF has been shown to improved motor neuron survival and axon
regeneration, efficient protein delivery is required due to the short half-life and poor tissue
penetration of neurotrophic factors

127,128,173

. Gene therapy through adeno-associated and

lentiviral-mediated methods of neurotrophic factors delivery ensures the local availability for the
entire regeneration period

6,9,129

. However, we and others have shown that uncontrolled
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overexpression of GDNF causes a “candy-store” effect, where axons do not extend beyond sources
of GDNF expression and are entrapped at a site with high levels of GDNF overexpression 6,8,9,130,174.
Either by directly injecting lentiviral vectors for GDNF overexpression or transplanting SCs that
overexpress GDNF at the injury site, large numbers of motor axons and SCs packed in coiled
formations are observed at the GDNF expression site 6,9,130,132. The negative side effects create a
major barrier against using GDNF to promote axonal regeneration.
In a previous study, we developed a microfluidic device to recapitulate the “candy-store”
effect in vitro and examined the effects of GDNF overexpressing SCs (G-SCs) on neuronal axon
entrapment 174. Similar to in vivo results, we found that G-SCs promote significantly greater axon
trapping compared to normal SCs, indicating that G-SCs can entrap neurites in vitro. In the present
study, we investigated the effects of pre-conditioning SCs with high GDNF levels and found that
such treatment can also cause axon entrapment. In addition, we showed that axon entrapment
caused by G-SCs could not be overcome by distal source of high GDNF levels (G-SCs), whereas
entrapment caused by pre-conditioned SCs can be overcome by high GDNF. Previously, we also
showed that soluble GDNF alone is sufficient to cause axon entrapment. To harness the growthpromoting effect and reduce the negative impacts of GDNF, it is important to understand the
mechanism by which GDNF overexpression causes entrapment. To this end, we examined genes
that are differentially expressed after exposing neurons to high GDNF levels and investigated
potential gene targets that might contribute to axon entrapment using lentiviral-mediated mRNA
knockdown. We identified that SLIT and NTRK like family member 4 (SLITRK4) was highly
expressed in neurons treated with high levels of GDNF and that shRNA knockdown of SLIKTR4
in neurons significantly decreased neurite entrapment in vitro.
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3.3 Materials and Methods
3.3.1 Microfluidic Device Fabrication:
Master molds were fabricated as described previously

175

. Briefly, 3-inch silicon wafers

(Silicon Inc. ID, USA) were coated with SU-8 2 photoresist (MicroChem Corp, MA, USA) using
a spin-coater. Exposing the photoresist under UV covered by the photomask forms the pattern for
the microchannels. A layer of SU-8 2050 was then used to form the pattern for the cell culture
chambers. Polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning, MI, USA) was poured onto
the silicon master mold in a petri dish with a 1:10 weight ratio of curing agent to the base and put
under vacuum to remove air bubbles. The PDMS was cured at 60°C overnight. The device was
then cut out and bonded to a glass slide using a plasma cleaner (Plasma Clean PDC-001, Harrick
Plasma Inc., NY, USA). After 20 minutes of UV sterilization, the completed device was coated
with 0.01% poly-L-ornithine (PLO) for 1 hour at 37°C and laminin (1 mg/mL, Life Technologies,
CA. USA) for 1 hour at 37°C.

3.3.2 Isolation of Sensory Neurons and Culture Conditions:
Sensory neurons were harvested from White Leghorn chicken embryos (Texas A&M
University, Texas, USA) at embryonic day 7-9. Dorsal root ganglia were isolated from embryos
and dissociated using 0.25% trypsin-EDTA (Invitrogen, CA, USA) for 20 minutes at 37°C.
Dissociated neurons were seeded in the somal chamber at 85,000 cells/cm2 and cultured in
neurobasal medium with 2% B27 supplement, 1% penicillin-streptomycin (Pen/Strep), and 1%
GlutaMAX (Invitrogen) (Fig. 3.1). Glial cell-line derived neurotrophic factor (GDNF, PeproTech,
NJ, USA) was applied to the middle and/or distal chamber. Medium in the somal chamber was
replaced with fresh medium every two days. Medium in the middle and distal chamber was also
replaced every two days to maintain the GDNF level. By replacing media every two days in all
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chambers, the volumes of each chamber were maintained. PTP IV inhibitor (Santa Cruz
Biotechnology, TX, USA) was dissolved in DMSO and applied at IC 50= 20μM according to
manufacturer’s recommendation. U73122 (Santa Cruz Biotechnology) was also dissolved in
DMSO and was applied at a concentration of 5μM. Trapping control for the inhibitor study also
has equal volumes of DMSO added.

3.3.3 Schwann Cell Harvest and Culture:
SCs were harvested from sciatic nerves collected from adult male Lewis rats using
previously described methods
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. To isolate the SCs, the sciatic nerve branches were placed in

DMEM (Dulbecco's Modified Eagle Medium) with sodium pyruvate (110 mg/L, Invitrogen),
Collagenase (10 mg/mL, Thermo Fisher), and 0.25% trypsin for 30 min at 37 °C. After triturating
the branches, they were centrifuged for 10 min at 500×g, and the cell pellet was washed with SC
medium containing DMEM plus 10% fetal bovine serum (FBS, Life Technologies) and 1%
Pen/Strep. The cells were then plated into a 100 mm petri dish coated with 0.1% poly-L-lysine
(Sigma) and laminin. Cytarabine (Ara-C, 10 μM, Sigma) was added to the plate along with fresh
SC medium on Day 3 after plating. Then the cells were cultured in fresh SC medium supplemented
with 2 μM forskolin (BioGems, CA, USA) and cultured for 1-2 weeks before use.

3.3.4 Lentiviral Transduction of Dissociated DRGs and SCs:
Dissociated chick DRG neurons were seeded overnight before the virus was applied.
Lentiviral-shRNA particles were obtained from GeneTarget Inc (San Diego, CA). SLITRK4
(Sense strand: ACTATGCAAACTGCAGCTAAG) was silenced. A non-viral positive control
condition treated with 700 ng/mL of GDNF and negative control with scrambled shRNA and
GDNF treatment were used for comparison. The virus at MOI = 2.5 was applied to the cells. The
plates were then centrifuged at 300g for 5 min. The cells were left with virus overnight in the
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Figure 3.1: Diagram of experimental set up for neuron and SC co-cultures. Cartoon
depiction of 3-chamber microfluidic devices seeded with dissociated DRGs in the somal
chamber, and normal SCs or GDNF overexpressing SCs (G-SCs) in the middle or distal
chamber. The microfluidic devices are composed of 3 chambers connected through 2 sets of
microchannels with dimensions 5x5x500μm (LxWxH).

incubator. They were washed twice with neurobasal media and then cultured in neurobasal media
plus supplement with GDNF. The cells were cultured for 7 days before they were evaluated for
growth or collected for protein harvest. G-SCs were generated based on a protocol previously
developed 5,7. Briefly, full-length rat GDNF cDNA was cloned into a lentiviral expression vector
in which gene expression was driven by the ubiquitin promoter and coexpression of DsRed
fluorescent protein was enabled by an internal ribosomal entry site (IRES) element. The
lentiviruses expressing GDNF were produced in HEK 293T cells (Li Lab, Washington University
in St.Louis). SC cultures were transduced with lentiviral particles containing GDNF
overexpression vectors before passage 7. Cells were incubated with 2 μg/mL of polybrene (Santa
Cruz Biotechnology, TX, USA) in SC medium for 1 hour at 37°C, after which the lentiviral vectors
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containing GDNF were introduced (MOI = 35). Cells were then incubated with 2 μg/mL polybrene
and vector for 20 hours at 37°C. GDNF production level from the G-SCs was evaluated using
enzyme-linked immune-sorbent assay (ELISA, R&D Systems, MN, USA) according to previously
published results 5. G-SCs were seeded in the middle chamber at 100,000 cells/cm2. G-SCs
produced 106.2±6.8 ng/mL/day of GDNF in the middle chamber. Based on this GDNF production,
approximately 744 ng/mL of GDNF was produced over 7 days. Therefore, we used 700 ng/mL of
GDNF as the supra-physiological level to be applied in the middle chamber.

3.3.5 Immunocytochemistry and Data Quantification:
Immunocytochemistry (ICC) was performed on Day 6 after the start of neuronal culture.
Briefly, the cells in the device were fixed using 4% paraformaldehyde (Sigma) for 20 min. After
washing 3 times with PBS, the cells were permeabilized with 0.01% Triton X-100 (Sigma) for 20
min. The cells in the device were then blocked using 5% normal goat serum (NGS, Sigma) in PBS
for 1 hr. Primary antibodies used included anti-neurofilament (1:200 with 2% NGS in PBS, clone
3A10, Developmental Studies Hybridoma Bank, IA, USA) for neurons and anti-S100β (1:400 with
2% NGS in PBS, Polyclonal Rabbit Ant-S100, Dako, CA, USA) for SCs. After incubating with
primary antibodies overnight, the device was washed 3 times with PBS, and then secondary
antibodies were applied for 2 hrs. Hoechst 33342 was applied (1:1000 dilution) for 20 min after
washing the device with PBS, to visualize nuclei. The device was then imaged using a wide-field
fluorescence microscope (Leica DMi8, Leica, IL, USA). After acquiring images of the middle
chamber and microchannels, percentages of axons crossing were calculated based on the number
of neurites exiting the middle chamber divided by the number of neurites entering the middle
chamber (Fig. 3.1). Overlapping neurites in one microchannel were accounted for by tracing them
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for a short distance after exiting the microchannel, at which point the neurites disperse (typically
3-4 neurites, data not shown).

3.3.6 Gene Expression Analysis:
We used a DNA microarray to identify genes that were differentially expressed after high
GDNF treatment. Dissociated embryonic chicken DRG’s were treated with 0 or 700 ng/mL of
GDNF for 7 days with media changes every two days. RNA was harvested using the RNeasy kit
(QIAGEN, Valencia, CA). DNA microarray analysis was performed by the Genomics and
Microarray Core at the University of Texas Southwestern using Affymetrix Chicken 1.0 ST array
(Thermo Fisher). Data analysis was performed using the Transcriptome Analysis Console
provided by Thermo Fisher. Data were normalized using the robust multiarray average. Statistical
significance was evaluated using T-test with empirical Bayes statistics with p < 0.05 for a fold
change of > |2|. False discovery rate was analyzed using the Benjamini-Hochberg procedure.
Microarray analysis of G-SCs was published elsewhere 156.
We then used quantitative real-time PCR (qRT-PCR) to confirm the differential expression
of selected genes. After harvesting RNA from dissociated DRGs, cDNA was made using the High
Capacity RNA-to-cDNA Kit (Life Technologies, Carlsbad, CA). TaqMan Fast Advanced Master
Mix (Life Technologies) was combined with TaqMan Gene Expression Assays (Life Technologies;
Table X) and cDNA for qRT-PCR. Reactions were performed using a Step One Plus Applied
Biosystems thermocycler (Life Technologies) with the following protocol: First stage: 1 cycle of
4.14 °C/s up to 95 °C for 20 s; Second Stage: 40 cycles of 95 °C for 1s and 3.17°C/s down to 60 °C
for 20s. The number of cycles necessary for the fluorescent intensity to increase exponentially, Ct
values, were recorded and normalized to GAPDH expression for Chick DRGs and β-actin for rat
Schwann cells. The comparative ΔCt method176 was used to analyze the mRNA expression levels
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of GDNF treated and untreated dissociated DRGs. Fold differences in relative mRNA expression
levels over the control cultures were reported for each gene (n = 3 for all groups).

3.3.7 Western Blotting:
Proteins from dissociated DRGs were harvested with radioimmunoprecipitation assay
buffer (RIPA buffer, 150mM sodium chloride, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1%
SDS, 50mM Tris, pH 8.0) with protease inhibitor cocktail (Thermo Fisher). The protein
concentration of the solution was determined using a Bradford protein assay (Thermo Fisher), and
equal volumes of 2x Laemmli sample buffer were added. The samples were boiled for 5 minutes
at 95 °C, and β-mercaptoethanol (10%, Life Technologies) was added before running on 4%–15%
mini-PROTEAN TGX gradient gels (Bio-Rad, Hercules, CA) at 100 V for 1.5 hours. The western
transfer was performed using the Trans-Blot Turbo Transfer System (Bio-Rad). The membrane
was then probed with the following antibody dilutions overnight: SLITRK4 1:1000 (ab67308,
Abcam, Cambridge, MA) and GAPDH 1:1000 (GA1R, Thermo Fisher). Rabbit anti-mouse
(ab97046, Abcam) and goat anti-rabbit (ab6721, Abcam) horseradish peroxidase-conjugated
secondary antibodies were used at a dilution of 1:25,000 and 1:1500 respectively and were
incubated for 1 hour at room temperature before imaging using the UVP GelDoc-It2® (Analytik
Jena, CA, USA) imaging system.

3.3.8 Statistical Analysis:
One-way ANOVA was performed on the sample groups using Minitab software.
Bonferroni posthoc test with p<0.05 for significance was used. Data represented were shown as
mean ±standard deviation. Data included N = 8 or more devices per condition; n=30-518 neurites
measured per device.

50

3.4 Results
3.4.1 Axon entrapment caused by GDNF-overexpressing Schwann cells (G-SCs)
cannot be overcome by distal G-SCs
Our previous studies showed that G-SCs could cause trapping both in vitro and in vivo 6,7,175.
In this study, we wanted to examine whether entrapment by G-SCs can be overcome by cues distal
to the G-SCs. Compared to seeding normal SCs in the middle chamber and no GDNF in the distal
chamber (SC/-, 59.3±12.3% crossing), all conditions with G-SCs seeded in the middle chamber
resulted in axon entrapment (G-SC/-, G-SC/SC, G-SC/G-SC, Fig. 3.2). More importantly, normal
SCs or G-SCs seeded the in the distal chamber did not significantly improve axons crossing the
middle chamber (G-SC/SC, 29.4±7.3% and G-SC/G-SC, 33.4±18.5% crossing, respectively) when
entrapment occurred with G-SCs in the middle chamber. This result is similar to the effect of
soluble GDNF has on axons, where high GDNF levels in the distal chamber cannot overcome axon
entrapment caused by high GDNF levels in the middle chamber 175.

3.4.2 Axon entrapment caused by pre-conditioned SCs can be reduced by high
GDNF levels or G-SCs in the distal chamber
Different SC phenotypes can impact the regeneration process. It has been shown that motor
nerves repaired with sensory nerve grafts can impair the regeneration process 46,177. We and others
have shown that pre-conditioning SCs with GDNF can overcome sensory or motor SC phenotypic
memory and improve regeneration with mismatched combinations of neurons and SCs (e.g., motor
neurons with sensory SCs)

126,178

. This result led us to investigate whether pre-conditioning SCs

with high GDNF concentrations can also induce SCs to cause trapping. We found that preconditioning SCs with 700 ng/mL of GDNF can significantly increase trapping (preSC700/-,
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22.6±15.1% crossing) compared to untreated SCs (SC/-, 59.3±12.3% crossing) (Fig. 3.3C).
Adding 100 ng/mL of GDNF in the distal chamber did not overcome this effect (preSC700/100,
29.2±6.1% crossing, Fig. 3.3C). However, both applying G-SCs or 700 ng/mL of GDNF in the
distal chamber can overcome trapping (preSC700/G-SC, 67.5±16.4% crossing, and preSC700/700,
54.5±22.4% crossing, Fig. 3.3C). Applying 700 ng/mL of GDNF in the middle chamber after SCs
pre-conditioning with no GDNF in the distal chamber did not overcome trapping with axons
crossing at 28.5±16.3% (preSC700Cont700), which was significantly different from all groups
except preSC700/- and preSC700/100 (Fig. 3.3C).

3.4.3 SLITRK4 is involved in axon entrapment induced by GDNF
Previously, we showed that high levels of soluble GDNF alone are sufficient to cause axon
entrapment in vitro

174

. To understand how GDNF is able to negatively influence

52

Figure 3.2: GDNF-Overexpressing Schwann Cells cannot overcome trapping in the
middle chamber. A-B) Normal SCs seeded in the middle chamber promoted axon growth and
axons crossing the middle chamber (A) whereas G-SCs seeded in the middle chamber impeded
axons crossing (B). Normal SCs (C) and G-SCs (D) seeded in the distal chamber cannot
overcome trapping caused by G-SCs in the middle chamber. E) Quantifications of axons
crossing. N = 8. *: p<0.0005, **: p<0.005, ***: p<0.01 compared to SC/- condition.
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axon growth, we performed DNA microarray analysis on dissociated DRGs treated with 0 or
700ng/mL of GDNF for 7 days. There were 101 differentially expressed genes with 36 upregulated and 65 down-regulated (Fig. 3.4A). A list of genes refined by literature is presented (Fig.
3.4B). The complete list of differentially expressed genes is provided in the supplementary data
(Table S3.1). These genes are at least 2 fold increased or decreased in expression and are known
to be related to axonal guidance and outgrowth. In particular, SLIT and NTRK like family member
4 (SLITRK4) and protein tyrosine phosphatase receptor type O (PTPRO) have been shown to
affect axon guidance and outgrowth. SLITRK family proteins are known to regulate neurite
outgrowth

179

. PTPRO is expressed in TrkB+ and Ret+ DRG neurons and serves as a negative

regulator of GDNF signaling

180

. To verify the DNA microarray results for these two genes, we

used qRT-PCR to evaluate the mRNA levels of the genes (Fig. 3.4C). SLITRK4 showed an increase
of 6-fold compared to untreated DRGs while PTPRO showed a greater than 2-fold increase. Based
on its role in axon growth and higher expression level, we decided to further investigate the role
of SLITRK4 in axon entrapment.
We used short-hairpin RNA vectors for SLITRK4 delivered through lentivirus to knock down
the gene expression in neurons cultured in the microfluidic device to examine the effects on axon
entrapment. The SLITRK4 knock-down group showed significantly higher axons crossing
(56.6±21.2% crossing) than the trapping control (22.6±11.5% crossing, treated only with
700ng/mL of GDNF in the middle chamber) and the scrambled shRNA groups (34.2±8.3%
crossing, Fig. 3.5A-D). The knockdown was confirmed through protein expression by Western
blotting (Fig. 3.5E & F). In addition, we selected two inhibition targets downstream of SLITRK4
signaling, protein tyrosine phosphatase σ (PTP σ) and phospholipase C (PLC) to further verify the
function of SLITRK4. The SLITRK family has been shown to interact with PTP type receptors
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181,182

. Specifically, SLITRK4 interacts with PTP σ. Using the PTP IV inhibitor, we examined the

effects of PTP inhibition on axon entrapment. Y791 in TrkA show some degree of homology with
the cytoplasmic tail of SLITRKS, Y945, raising the question of whether SLITRKS are also
implicated in PLC-γ signaling 179. Therefore, we used a PLC inhibitor, U73122, in an attempt to
reduce

axon

entrapment.

Figure 3.3: GDNF pre-conditioned SCs show trapping that is reversible. A) Untreated
SCs did not show trapping whereas SCs pre-conditioned with 700ng/mL of GDNF (B)
showed trapping. C) More importantly, this trapping can be reversed by 700ng/mL of GDNF
or G-SCs in the distal chamber (preSC700/G-SC & preSC700/700). N=8. *: p<0.05.
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PTP IV inhibitor significantly increased axons crossing (38.8±8.7% crossing) compared to the
trapping control; whereas U73122 did not improve axons crossing (34.8±15.9% crossing).

3.5 Discussion
GDNF is an important component in nerve regeneration, affecting both neurons and SCs.
It is known to attract axons, promote neuronal survival, and improve remyelination of regenerating
axons

122–124,148,183

. At the same time, GDNF has been shown to directly affect SC proliferation,

migration, and differentiation, all of which are essential steps of the axonal regeneration processes
124,170,184,185

. However, the window of endogenous GDNF release by the SCs is often too short for

distal nerve injuries due to chronic denervation, leading to inadequate recovery 30. Although gene
therapy through adeno- and lentiviral mediated transductions prolongs GDNF release for the entire
regeneration process, we and others have found that the overexpression of GDNF can severely
reduce axonal growth and cause axon entrapment, leading to the “candy-store” effect 6,8,9,175. The
mechanism underlying the “candy-store” effect is still unknown. In our previous study, we
developed an in vitro culture platform that aims to dissect this phenomenon by individually testing
the possible factors that cause axon entrapment 175. In this study, we further examined the effects
of GDNF on SCs’ ability to promote axon growth, as well as the molecular pathways in neurons
activated by high GDNF levels.
Here, we showed that both SCs and G-SCs in the distal chamber could not overcome
trapping caused by GDNF-overexpressing SCs in the middle chamber (Fig. 3.2).
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Figure 3.4: Gene expression differences between dissociated DRGs that are untreated
or treated with 700ng/mL of GDNF. A) Differential gene expression analysis (data
inclusion criteria: fold change > |2|, p<0.05) Statistical analysis: Benjamini-Hocherg
procedure. B) Selected gene lists based on fold change and relationship to axonal guidance
and outgrowth. C) qRT-PCR of SLITRK4 and PTPRO relative to untreated DRGs. N=3, *:
p<0.05 compared to untreated groups.

These results were similar to axon entrapment caused by high levels of soluble GDNF alone. High
levels of GDNF in the distal chamber were not able to overcome trapping in the middle chamber
175

. Interestingly, we found pre-conditioned SCs with high levels of GDNF can also cause trapping.

However,

the

entrapment

was

reversible
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by

either

seeding

G-SCs

or

applying

Figure 3.5: SLTITRK4 shRNA knockdown on dissociated DRGs. A-C)
Immunocytochemistry staining of neurofilaments on dissociated DRGs treated with 700
ng/mL of GDNF. A) Trapping control treated with 700ng/mL of GDNF but no shRNA.
B) Scrambled shRNA that should not silence SLITRK4. C) SLITRK4-shRNA treated.
D) Quantifications of axons crossing the middle chamber of the knockdown study. N =
11-16, *: p<0.005. E) Western blot analysis of SLITRK4 protein with GAPDH as
control F) Densitometry of the Western blot SDS-PAGE gel. N = 3, *: p<0.05. G)
Quantifications of axons crossing the middle chamber where DRGs are treated with
inhibitors of PTP (PTP IV inhibitor) and Phospholipases C (U73122). N = 8, *: p<0.05
compared to positive control.
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700

ng/mL of GDNF in the distal chamber. These results may indicate that GDNF-induced axon
entrapment is irreversible with continuously high GDNF treatment. In contrast, preconditioning
SCs with GDNF induced axon entrapment that can be reversed with high GDNF sources distal to
the SCs. It has been shown that GDNF treatment of SCs can induce a positive feedback pathway
that allows SCs to secrete more GDNF

122,126

. Based on the results of the current study, pre-

conditioned SCs might cause axon entrapment through endogenous GDNF production by the SCs.
However, such GDNF level might not be sufficient to cause more permanent trapping and can be
overcome by high levels downstream. Marquardt et al. showed that by temporally controlling
GDNF release, various degrees of axon growth was achieved 6. With 8 weeks of continuous GDNF
release, axon entrapment occurred in vivo; 4 weeks of GDNF release was not sufficient for axons
to cross the 30 mm sciatic nerve defect in rats; while 6 weeks of GDNF release allowed for axons
to cross the injury gap and did not cause axon entrapment. These results together seem to suggest
the duration of high levels of GDNF can determine whether the effect on axons is beneficial or
detrimental.
Ee et al. have shown that G-SCs have a distinct gene expression profile compared to normal
SCs

156

. One of the highly expressed gene target neuropeptide Y (NPY) is well studied and is

known to be involved in axon growth. We examined its effects on axon growth in our device, but
the results did not show any axon entrapment when applied in high concentrations (data not shown).
We also examined whether applying high levels of GDNF to pre-conditioned SCs would further
increase axon entrapment (Fig. 3.3C, preSC700Cont700). We did not observe any increase in axon
entrapment, which may suggest the effects of pre-conditioned SCs trapping neurites and GDNF
trapping neurites were not additive. We and others have shown that GDNF overexpression can
cause the formation of irregular fiber networks at GDNF depot 8,130,156,175. Specifically, G-SCs can
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cause accumulation of axons, as well as irregular axon sprouting while normal SCs did not. This
might be attributed to the interaction of G-SCs with fibroblasts, which can result in significantly
ECM remodeling

156

. Interestingly, SCs pre-conditioned with high levels of GDNF also

demonstrated similar characteristics. While both untreated SCs and SCs pre-conditioned with low
levels of GDNF showed relatively smooth neurites growing along them, both G-SCs and SCs preconditioned with high levels of GDNF showed neurites with more sharp turns or kinks (Fig. 3.2AD and Fig.3A-B). In contrast, even though soluble GDNF can cause axon entrapment, it did not
show similar fiber network formation 175. Together, these results suggest GDNF and SCs constitute
as different components of the “candy-store” effect.
To further understand how GDNF can affect neurite outgrowth, we analyzed the gene
expression profile of dissociated DRGs treated with high GDNF. Through screening, we identified
SLITRK4 as a likely candidate that may contribute to the axon entrapment. The SLITRK family
proteins have been implicated in controlling axon outgrowth, promoting neuronal survival, and
forming synapses 179,186,187. Initial studies have shown that expression of SLITRKs in PC12 cells
can decrease the number of neurites with NGF treatment

179

. Further investigations show that

SLITRK1 can improve the dendritic length of the cortical neurons in vitro

186

. Similarly,

SLITRK5-knockout mice showed a marked decrease in dendritic complexity of medium spiny
neurons in the striatum 187. With selectively high expression in the inner ear, SLITRK6 promotes
the survival and neurite outgrowth of sensory neurons of the inner ear

188

. Interestingly, Slitrk6-

knockout mice showed decreased protein levels of TrkB and TrkC, which suggests a role in
modulating the neurotrophin signaling pathway. Common to all SLITRK family proteins are the
leucine-rich repeats (LRR). Linx, for example, is an LRR and immunoglobulin family protein that
interacts with Ret, which is the receptor of GDNF in neurons 189. While no previous studies have
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investigated the direct link between GDNF and SLITRK4, our findings showed that high GDNF
could increase SLITRK4 gene expression.
All six Slitrks are also synaptogenic, as demonstrated by artificial synapse-formation assay
190,191

. With the exception of SLITRK3, which is specifically localized to inhibitory synapse and

interact with presynaptic protein tyrosine phosphatase δ (PTPδ), all other SLITRK proteins are
involved in excitatory synapse formation and interact with PTPσ

190,191

. Based on this result, we

wanted to examine whether inhibiting PTPσ can affect SLITRK4 signaling pathway. Our results
indicate that using PTP IV inhibitor can reduce axon entrapment. This further strengthens the
relationship between SLITRK4 and axon entrapment. Another gene target that was upregulated in
our DNA microarray assay was PTPRO, which is involved in excitatory synapse formation

192

.

Many studies have shown that GDNF not only promotes axon growth but also synapse formation.
In a seminal study, Ledda et al. showed GDNF and its receptor, GFRα1 promote synapse formation
by ligand-induced cell adhesion

193

. Together, these findings suggest that GDNF can form both

direct cell-cell interactions as well as increase the expressions of other genes, such as SLITRK4
and PTPRO, to promote synapse formation.
In this study, we investigated how high levels of GDNF can impact SCs ability to promote
axon growth and the underlying mechanisms by which GDNF can cause axon entrapment. We
showed that axon entrapment by G-SCs could not be overcome with other sources of high levels
of GDNF, including G-SCs. In contrast, axon entrapment caused by SCs pre-conditioned with high
GDNF levels can be rescued by distal sources of high GDNF. Through gene expression analysis
and gene-silencing studies, we were able to demonstrate that SLITRK4 plays an important role in
axon entrapment. In conclusion, these results may prove valuable in understanding the effects of

61

GDNF on both SCs and neurons, providing guidance towards developing better GDNF delivery
methods to establish a potential therapeutic for PNI.
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3.6 Supplementary Data
Table S3.1 Complete List of Differentially Expressed Genes in Dissociated DRGs Treated with
700ng/mL of GDNF
Fold
Gene Symbol
Change FDR P-val
Description
potassium voltage-gated channel, modifier subfamily S,
KCNS3
3.92
0.0136 member 3
secreted phosphoprotein 1; polycystic kidney disease 2
SPP1; PKD2
3.45
0.1062 (autosomal dominant)
HS3ST1
3.38
0.0863 heparan sulfate (glucosamine) 3-O-sulfotransferase 1
heparan sulfate glucosamine 3-O-sulfotransferase 1LOC423822
3.36
0.0308 like
TMEM233
2.89
0.0136 transmembrane protein 233
PLCL1
2.87
0.0353 phospholipase C-like 1
C17ORF58
2.87
0.0148 chromosome 18 open reading frame, human C17orf58
LOC395159
2.77
0.1046 Schwann cell-specific EGF-like repeat autocrine factor
BCO2
2.75
0.1117 beta-carotene oxygenase 2
CBLN2
2.54
0.0218 cerebellin 2 precursor
transcription factor AP-2 beta (activating enhancer
TFAP2B
2.47
0.0154 binding protein 2 beta)
phosphatidylinositol-specific phospholipase C, X
PLCXD2
2.46
0.0613 domain containing 2
SERTM1
2.38
0.0447 serine-rich and transmembrane domain containing 1
DLGAP2
2.37
0.0791 discs, large (Drosophila) homolog-associated protein 2
SLITRK4
2.35
0.0136 SLIT and NTRK-like family, member 4
UGT8
2.29
0.0136 UDP glycosyltransferase 8
VIT
2.29
0.0451 vitrin
RET
2.27
0.0136 ret proto-oncogene
CACNG2
2.27
0.0757 calcium channel, voltage-dependent, gamma subunit 2
SOSTDC1
2.22
0.1909 sclerostin domain containing 1
LIPG
2.19
0.2019 lipase, endothelial
PTPRO
2.16
0.0579 protein tyrosine phosphatase, receptor type, O
TMEM163
2.12
0.0319 transmembrane protein 163
VILL
2.12
0.1644 villin-like
PTPRT
2.11
0.0218 protein tyrosine phosphatase, receptor type, T
SV2B
2.09
0.0234 synaptic vesicle glycoprotein 2B
LOC101750415
2.09
0.1646 uncharacterized LOC101750415
CNTN4
2.08
0.0248 contactin 4
ATPase, H+ transporting, lysosomal accessory protein 1ATP6AP1L
2.06
0.0447 like
HAND2
2.06
0.1164 heart and neural crest derivatives expressed 2
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MAB21L1

2.05

KCNA1
GRPR
VLDLR
SLITRK4
CHAT
CHODL
C10ORF112
CSRP1
LOC422513
TNFRSF1B

2.05
2.02
2.01
2.01
2
-2.04
-2.04
-2.05
-2.06
-2.06

SLC2A12
SELENBP1;
LOC100857226
PODN
DSC2
TLR3
SLC38A4
MCTP1
FIBIN
MYLK

-2.07

BBOX1
PRRX1
VIP
IL1RL1
PALMD
CDC42EP3
MYL9
AVPR2
LMO7
FAM83B
PID1
PDGFD
FAM180A
COLEC10

-2.13
-2.13
-2.14
-2.14
-2.16
-2.17
-2.18
-2.18
-2.25
-2.25
-2.27
-2.29
-2.31
-2.31

ERG

-2.33

MYH1D

-2.35

-2.08
-2.08
-2.1
-2.11
-2.11
-2.12
-2.12
-2.12

0.0428 mab-21-like 1 (C. elegans)
potassium voltage-gated channel, shaker-related
0.0295 subfamily, member 1 (episodic ataxia with myokymia)
0.1097 gastrin-releasing peptide receptor
0.0381 very low density lipoprotein receptor
0.0148 SLIT and NTRK-like family, member 4
0.0218 choline O-acetyltransferase
0.2272 chondrolectin
0.0428 chromosome 2 open reading frame, human C10orf112
0.042 cysteine and glycine-rich protein 1
0.1919 hect domain and RLD 4-like
0.0604 tumor necrosis factor receptor superfamily, member 1B
solute carrier family 2 (facilitated glucose transporter),
0.0319 member 12
selenium binding protein 1; selenium-binding protein 10.232 A-like
0.0715 podocan
0.0455 desmocollin 2
0.0977 toll-like receptor 3
0.0353 solute carrier family 38, member 4
0.0727 multiple C2 domains, transmembrane 1
0.1217 fin bud initiation factor homolog (zebrafish)
0.0926 myosin light chain kinase
butyrobetaine (gamma), 2-oxoglutarate dioxygenase
0.0578 (gamma-butyrobetaine hydroxylase) 1
0.0839 paired related homeobox 1
0.0525 vasoactive intestinal peptide
0.0451 interleukin 1 receptor-like 1
0.0248 palmdelphin
0.0562 CDC42 effector protein (Rho GTPase binding) 3
0.0674 myosin, light chain 9, regulatory
0.1221 arginine vasopressin receptor 2
0.0525 LIM domain 7
0.1385 family with sequence similarity 83, member B
0.1498 phosphotyrosine interaction domain containing 1
0.0218 platelet derived growth factor D
0.12 family with sequence similarity 180, member A
0.1252 collectin sub-family member 10 (C-type lectin)
v-ets avian erythroblastosis virus E26 oncogene
0.0319 homolog
myosin, heavy chain 1D, skeletal muscle (similar to
0.1282 human myosin, heavy chain 1, skeletal muscle, adult)
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RIPK3
MYL10
PENK

-2.43
-2.44
-2.47

SVEP1
FHL2

-2.51
-2.52

NEDD9
LOC396531
ACTC1
CYTL1
MYL1
PRRX2
SIK1
GDF10
PKP2
ENPP3
STEAP1
PDLIM3

-2.58
-2.59
-2.61
-2.61
-2.63
-2.65
-2.67
-2.69
-2.86
-2.88
-3.01
-3.04

SLCO2A1
SLC39A8

-3.05
-3.15

KCNMB1
A2ML3; A2M
MMP27
PDPN
LOC422264
KRT15
KRT19
NEXN
ITGBL1
OMD; ASPN
EFEMP1
STEAP1
PAWR
NOV
COCH
C7

-3.15
-3.17
-3.19
-3.2
-3.24
-3.27
-3.45
-3.79
-3.88
-3.96
-3.99
-4.08
-4.23
-5.19
-5.98
-8.01

0.0218 receptor-interacting serine-threonine kinase 3
0.0639 myosin, light chain 10, regulatory
0.0218 proenkephalin
sushi, von Willebrand factor type A, EGF and pentraxin
0.0356 domain containing 1
0.219 four and a half LIM domains 2
neural precursor cell expressed, developmentally
0.0439 down-regulated 9
0.0608 parvalbumin
0.0493 actin, alpha, cardiac muscle 1
0.0795 cytokine-like 1
0.0538 myosin, light chain 1, alkali; skeletal, fast
0.0921 paired related homeobox 2
0.0218 salt-inducible kinase 1
0.0791 growth differentiation factor 10
0.12 plakophilin 2
0.0596 ectonucleotide pyrophosphatase/phosphodiesterase 3
0.0519 six transmembrane epithelial antigen of the prostate 1
0.0202 PDZ and LIM domain 3
solute carrier organic anion transporter family, member
0.0863 2A1
0.0552 solute carrier family 39 (zinc transporter), member 8
potassium channel subfamily M regulatory beta subunit
0.0854 1
0.0418 alpha-2-macroglobulin-like 3; alpha-2-macroglobulin
0.0356 matrix metallopeptidase 27
0.0202 podoplanin
0.0579 protocadherin-11 X-linked-like
0.3031 keratin 15
0.0326 keratin 19
0.1058 nexilin (F actin binding protein)
0.1015 integrin, beta-like 1 (with EGF-like repeat domains)
0.0353 osteomodulin; asporin
0.0525 EGF containing fibulin-like extracellular matrix protein 1
0.0761 six transmembrane epithelial antigen of the prostate 1
0.0609 PRKC, apoptosis, WT1, regulator
0.0525 nephroblastoma overexpressed
0.1607 cochlin
0.1897 complement component 7
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Chapter 4: Summary of Findings and Future
Directions
4.1 Summary of Findings
This body of work has sought to elucidate the mechanism of the “candy-store” where high
levels of GDNF can affect both the SCs and neurons. The results shown in this thesis suggest that
high levels of soluble GDNF alone are sufficient to cause the “candy-store” effect and that Slitrk4
is involved in the process of axon entrapment. Consistent with the in vivo results, GDNFoverexpressing SCs also induced axon entrapment in vitro. In addition to axon entrapment, dense
fiber networks formed along GDNF-overexpressing SCs. These results suggest that the “candystore” effects consist of two parts, where axon trapping is caused by GDNF directly, and fiber
networks form in the presence of GDNF-overexpressing SCs. These results were found through
two studies whose objectives included: to develop a culture platform that can recapitulate axon
entrapment in vitro; to evaluate the effects of supra-physiological concentrations of GDNF on axon
entrapment and SC response.
The first study of this thesis developed an in vitro platform that can be used to model axon
entrapment observed with high GDNF from transgenic overexpression seen in previous in vivo
studies. The three-chamber culture platform allowed neurons to be seeded in one end chamber
while the effect of various trapping conditions in the other two chambers was used to study neurite
entrapment. Firstly, we verified that GDNF-overexpressing SCs could cause axon entrapment in
vitro. It was also found that supra-physiological levels of GDNF alone were sufficient to induce
axon entrapment. Moreover, equally high levels of GDNF distal to the entrapment sites cannot
overcome such an effect. Importantly, soluble GDNF did not cause axon coil formation suggesting
two separate roles of GDNF and SCs in contributing to the “candy-store” effect.
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The second study of this thesis focused on understanding whether GDNF is affecting the
neurons directly or SCs affected by GDNF are causing axons to trap. Similar to soluble GDNF,
GDNF-overexpressing SCs can induce axon entrapment that cannot be reversed by distal sources
of high GDNF. In contrast, while pre-conditioning SCs in high levels of GDNF can also cause
axon entrapment, such effect can be reduced by distal sources of high GDNF levels. When
evaluating the direct effects of GDNF on neurons, we found that SLITRK4 was significantly
upregulated when dissociated DRGs are treated with high concentrations of GDNF. It was
confirmed through SLITRK4-shRNA knock-down studies, that axon entrapment was significantly
reduced. Furthermore, inhibition of SLITRK4 ligand, PTPσ also reduced axon entrapment and
further verified the role of SLITRK4 in causing axon entrapment when treated with high
concentrations of GDNF.

4.2 Future Directions
4.2.1 Understanding the Roles of GDNF in Affecting SCs
Findings of this work highlight the importance of GDNF’s effects on SCs. Our results
showed that GDNF-overexpressing SCs in vitro were able to demonstrate similar effects to that of
in vivo. Besides axon entrapment, the formation of axon coils was also present with GDNFoverexpressing SCs. This morphology was absent when neurons are treated with soluble GDNF,
suggesting the importance of SC-axon interactions. SCs were shown to closely interact with their
surrounding microenvironment, including axons and fibroblasts, through cell-cell signaling 194. In
addition, GDNF overexpression can significantly alter the gene expression of SCs 123,156. Therefore
it might be important to study the presence of cell membrane proteins and understand how they
might affect axon guidance and induce axon coil formation. Another potential interaction of SCs
with its microenvironment might be SCs remodeling the surrounding ECM, which may cause the
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formation of axon coils. Ee et al. showed that the interaction between G-SCs and fibroblast could
significantly affect the surrounding ECM

156

. It would be interesting to understand whether the

remodeled ECM can also affect axon guidance and axon coil formation.
The results of the second study indicated that axon entrapment caused by SCs preconditioned with high GDNF could be reversed by distal sources of high GDNF. In contrast, both
soluble GDNF and G-SCs induced axon entrapment that cannot be overcome. These results seem
to suggest that the constitutive presence of high GDNF levels can induce more permanent trapping
compared to pre-conditioned SCs. It is known that GDNF can induce the production of GDNF in
SCs through a positive feedback loop 122. Therefore, it might be worth investigating the levels of
GDNF production in SCs pre-conditioned with high GDNF concentrations to better understand
the differences in GDNF levels between permanent and non-permanent trapping. This might help
develop better strategies that optimize GDNF release to prevent permanent axon entrapment.

4.2.2 Combining SLITRK4 Inhibition with GDNF Overexpression for Nerve
Regeneration
This body of work has demonstrated that high levels of GDNF treatment can increase
SLITRK4 expression. Many SLITRK family proteins, except SLITRK4, demonstrated roles in
synapse formations

179

. While the exact functions of SLITRK4 are unknown, the leucine-rich

repeats (LRR) of the protein may be involved in modulating the neurotrophin signaling pathways
through TrkB and TrkC

188

. Linx, an LRR protein, has been demonstrated to interact with Ret,

which is a GDNF receptor expressed in neurons 189. Many studies have also shown that GDNF can
significantly increase muscles innervation through synapse formation at neuromuscular junctions
119,195

. Our studies suggest that GDNF is involved in the regulation of SLITRK4 expression. It may

be valuable to know the molecular pathway of how one protein is affecting the other. By interfering
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with such signaling pathway, we may be able to reduce the trapping effect of GDNF
overexpression and only harness its beneficial effect of promoting axonal growth. In addition, the
functions of SLITRK4 can be further elucidated.
This thesis also demonstrated that the knock-down and inhibition of SLITRK4 could
reduce axon entrapment in vitro. Future studies using animal models can be used to investigate the
combined effects of GDNF overexpression and SLITRK4 inhibition. Either by transplanting
GDNF-overexpressing SCs in a scaffold or directly injecting GDNF overexpression transduction
viral vectors at the site of injury, inhibition of SLITRK4 through shRNA could be delivered at the
same time to examine whether axon entrapment still occurs. Alternatively, inhibition of PTPσ can
be easily achieved by incorporating the inhibitors in the scaffold where the G-SCs were seeded.
By assessing the number of axons that could grow pass the GDNF depot, we could evaluate the
efficiency of such combinatory therapy in treating peripheral nerve injury in animal models.

4.2.3 Alternative Strategies of Controlled GDNF Delivery
Another approach for better using the potent effects of GDNF is through controlled release
of GDNF. Previously, our lab has experimented the using of the doxycycline-controlled release of
GDNF in vivo 6. It was shown that 4 weeks of GDNF release was insufficient for axon regeneration,
8 weeks of GDNF release resulted in the “candy-store” effect, and 6 weeks of GDNF release
achieved the best axon regeneration while avoided axon entrapment. This result highlighted the
advantage of controlled release compared to constitutive overexpression. The results of the current
thesis showed that axon entrapment caused by SCs pre-conditioned with high GDNF could be nonpermanent. Potential strategies can be developed to use the inducible release of GDNF at a nonpermanent trapping level. This will enable the repair scaffold to present the strongest signals to the
regeneration axons while avoiding the negative effect of permanent axon entrapment.
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Selecting different locations for GDNF overexpression should also be considered. Previous
studies showed that GDNF overexpression from muscle had a better effect on nerve regeneration
than central delivery from GFAP-expressing cells

185,196

. Since muscle cells are the final targets

for the motor neuron in PNS, myoblast might be a potential candidate for GDNF overexpression,
especially if the injury site is close enough to the overexpression site for axons to sense the trophic
effect.
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